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Abstract
An array of over the counter ophthalmic solutions (eye drops) is available for the
self treatment of minor ophthalmic disorders. They are used allover the world for the
treatment of minor eye episodes including redness, dry eye and tear generation. Because
components in ophthalmic solutions may cause adverse reactions, there is a need for
modern,

rugged

chemical

analysis

techniques

for

these

components

using

straightforward, inexpensive and readily available instrumentation and methods. This
work focuses on the chemical analysis of ophthalmic solutions in three major areas;
preservatives, lubricants, and active components. Each feature plays an integral part in
the total effectiveness of the ophthalmic solution, so several components were studied
extehsively with different chromatographic techniques. The emergence of new complex
matrices which target multi symptom relief in the eye makes development of
straightforward new techniques increasingly challenging.
One of the three primary aspects of this work was the analysis of preservatives,
which is important for inhibiting microbial growth and ensuring safety. Benzalkonium
chloride (BAC) is widely used in ophthalmic solutions and is often difficult to analyze
due to its multicomponent nature. Further, the several homologues do not posses identical
bactericidal activity, with the Cl2 homologue most effective against yeast and fungi, the
C14 homologue against gram-positive bacteria, and the C16 homologue against gram
negative bacteria. A fast, simple, isocratic, high performance liquid chromatography
based in ultra violet (HPLC-UV) detection method was sufficient to fully separate the
BAC homologues from each other and from other components in typical solutions.
Second, lubricants, or demulcents, are often present in ophthalmic solutions and
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are used to control the solution viscosity. Additionally, they offer a medicinal benefit,
relieving pain in inflamed or irritated mucous membranes. Three different demulcents
were studied: polyvinylpyrrolidone (PVP), polyethylene glycol 400 (PEG400) and
glycerin. As PVP and PEG400 are polymeric, size exclusion chromatography (SEC) is
the technique of choice, however, most SEC methods focus on molecular weight
characterization rather than quantitative analysis. In this work, total PVP in ophthalmic
solutions

was

determined

using the

unusual combination of size exclusion

chromatography, ultraviolet-visible detection and quantitation of an analyte peak that
elutes before the void volume disturbance. A more conventional size exclusion
chromatography method was used for the simultaneous determination of PEG400 and
glycerin in ophthalmic solutions, using size exclusion chromatography, with refractive
index detection.
Third, analysis of the active component, along with possible degradants and
impurities is critical in any ophthalmic solution. The increasing attention that degradants
and impurities are receiving from the regulatory authorities makes these methods
important to the development of ophthalmic solutions. One challenge in ophthalmic
solutions is the analysis of oxymetazoline hydrochloride (OXY) and its known
degradation

product

(N-(2-arninoethyl)-2-[4-(1,ldimethylethyl)-3-hydroxy-2,6

dimethylphenyl]-acetarnide) (OXY-DEG). Although a number of HPLC methods have
been developed to determine OXY in a variety of products, none of these methods also
determined OXY -DEG, which appears at much lower concentration. In this work, a
straightforward, isocratic reversed-phase HPLC-UV method was sufficient to quantify
both OXY and OXY -DEG in a single analysis, although their concentrations are orders of
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magnitude different. Forced degradation studies performed during method validation
revealed that OXY -DEG is likely a base hydrolysis product of OXY.
In the analysis of over the counter medications such as ophthalmic solutions,
which are widely used at low cost, there is an increasing need for new analytical methods
that are low cost, simple to operate and use straightforward instrumentation, while
maintaining similar sensitivity and reproducibility requirements to techniques employing
more sophisticated instrumentation. In this work, several straightforward techniques for
the analysis of components in ophthalmic solutions, each of which represents an
improvement over previous literature techniques, are demonstrated.
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Chapter 1: Introduction

1.1 Historical Overview

The history of ophthalmic solutions coincides with the history of Ophthalmology,
the branch of medicine that deals with the anatomy, physiology and diseases of the eye.
The word has Greek roots from the word "ophthalmos" which means eye and the word
"logos" which means speech, word, and communication of thought with words. Literally
the word ophthalmology means the science of eyes [1].
Due to unrecorded uncertainties in the history of ophthalmology, it is impossible
to say where exactly the treatment of the eyes began, but the earliest mention of any
medical matter is found to go back as far as 2000 B.C. Any medical treatment at that time
was totally at the hands of priests. The first written document about treatment of the eye
came later, around 1650 B.c. in Egypt where a 110 page document (Papyrus Ebers) was
found that described all the diseases and remedies that were known to Egyptians of that
time. From the 110 pages, around 8 pages were dedicated to diseases of the eye and
treatment for such diseases. Some of the remedies at the time used onions, castor oil,
pomegranate, copper salts, hemlock and opium. Learning and performing medicine at
that time was done at temples, as priests were doctors as well.
The separation of scientific medicine from temple practice was not completed
until 460 B.C. during the golden age of Greece. Hippocrates considered the father of
medicine is credited with accomplishing this separation by introducing the science of
observation and reasoning into medicine.
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In those days, ophthalmic diseases were treated with venesection, cupping and
occasionally by drawing the humours away from the eye. Chronic diseases were treated
mainly with local application of milk of women, gall of goats, and various preparations of
copper, iron, and lead. For the next 800 years and from the time of Hippocrates to the end
of the era of Roman Empire, Greek medicine dominates the field and was practiced not
only in Greece but extended to Rome and Alexandria.
The Alexandrian school introduced Collyria for treatment of eye diseases. It was a
solid substance made up of several secret ingredients in a cake form with gum being the
basis of the formulation. Prior to its application a fragment of the cake was dissolved in
water, oil, milk of women, urine, bile, or saliva.
During this time the disease that was scourge to the eyes was trachoma, an
infectious disease caused by bacteria which produce roughening of the inner surface of
the eyelids, causing the eyelids to turn inward and scratch the cornea eventually creating
a painful form of blindness.
The work of three men dominated medicine during this period: Celsus, Pliny, and
Galen. Celsus wrote "De Medica or De Medicina" in A.D. 29, a compilation of detailed
description of couching for cataract [2]. A humouraI implication, collected in a space
between the pupil and the lens, obstructing visual spirits. When this was fully developed
it could be displaced away from the front of the eye by means of an operation. Pliny
made the observation that the eyes of nocturnal animals were brilliant in the dark, in
agreement with other Roman writers of this period that were interested in the problem of
why the pupil is black. Pliny also credits the discovery of glass making to the
Phoenicians. In these early days, glass was used as an art; later glass is used to correct
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vision. Galen (A.D. 131-201) studied the anatomy of the eye and like Hippocrates,
thought that the crystalline body (lens) was the most important part of the organ of vision.
He believed that the retina was to perceive the alterations which occur in the crystalline
body of the eye and to communicate them to the brain. He shared the same ideas for
cataracts as Celsus.
During the period of A.D. 630-1375, medieval scientists combined theory and
.practice. They found it natural to study the eye with the practical applications of that
knowledge. This period also marked the rise of Islam and conquest of the Eastern part of
the Mediterranean. One unfortunate event it was the burning of the famous library of
Alexandria, resulting in a big gap in the ancient writings that was never restored. The
eastern knowledge of medicine began to filter into the west during the Crusades and
within a decade the torch had been handed on to Western Europe.
During the 16th and 17th centuries, the facts of physiological optics began to
slowly be accepted. Robert Hooke first measured the minimum visual angle which the
basis of our present day test types. However, clinical progress was not made until the
beginning of the 19th century especially in the area of cataracts. First, Daviel of France
published the operation of extracting the opaque lens from the eye through the interior
chamber and later Brisseau convinced the Academie Royal des Sciences that a cataract is
really an opaque lens.
The 19th century was marked by many discoveries in ophthalmology,
bacteriology, by the introduction of anesthesia, and antiseptic surgery just to mention a
few. However, from the perspective of ophthalmic solutions, bacteriology and the
introduction of antiseptic surgery highlight the importance of a bacteria free environment
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and the tools used for eye surgery. In those days, ophthalmic solutions were kept in
corked glass bottles, unpreserved, and were administered with a pipette. Current studies
show that solutions stored under these conditions are 94% contaminated [3]. These
results are not surprising since the pipette, the open bottle or the cork can come in contact
with a pathogenic microorganism, even in a clean environment. As Pasteur famously
demonstrated in 1864, contamination from microorganisms can be prevented with savvy
packaging [4].
Ophthalmic solutions in twentieth, and twenty-first centuries are marked in
improvements in packaging, preservation, and delivery systems that improve product
lifetime and sustain release of the drug in the eye. Packaging moved from glass cork
bottles to a sterile glass bottles with a screwed dropper, and in some instances to a plastic
bottle with a tip for directly delivering the drop into the eye.
Preservation of ophthalmic solutions is very important and is required by the Food
and Drug Administration for topical ophthalmic multidose bottles. More specifically, the
United States Pharmacopeia specifically states that ophthalmic solutions in multidose
containers should contain suitable substances to prevent or destroy micro-organisms
when accidentally introduced when the container is opened during use. Despite concerns
in recent years about the presence of benzalkonium chloride and the development of
other preservative systems, benzalkonium chloride is by far the preservative system of
choice in ophthalmic solutions.
Recent advances in ophthalmic solutions have focused on sustained release
formulations for delivering the drug into the eye and formulations that target multiple
symptoms at the same time. Because of the unique characteristics of the eye and the
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multiple barriers that the formulation has to go through, the development of ophthalmic
formulations is extremely challenging. In the next section, "formulation overview" these
challenges are described in more detail.

1.2 Formulation Overview

Ophthalmic solutions are among of the most challenging and fascinating tasks
facing product development researchers because the eye is well protected against the
absorption of foreign materials, including therapeutic formulations. The easy accessibility
of the eye makes this organ suitable for topical administration of a medication. However,
any drug delivered through that route must go through several barriers in the precorneal
area before the anatomical barriers of the cornea. Because of these barriers, only a small
dose of the drug will reach the eye.
Upon topical administration of an ophthalmic solution in the eye, tear flow
immediately increases and washes it away in a short period of time. Under normal
conditions, the eye can accommodate a small volume before overflowing. Commercial
eye drops typically deliver about 30

~L

to 50

~L

per drop and most of this amount will

drain out of the eye with the first blink. Due to that loss, only a small amount (about 10
~L)

will remain in the eye to penetrate the COTllea and the inner tissue of the eye [5].

Consequently there is a very small time window, approximately 5 minutes, for any drug
introduced topically to be absorbed by the eye and in many cases no more than 2% of the
drug absorbed [5-7]. By contrast, a considerable amount of drug is absorbed by the
nasolacrimal duct, with its greater surface area and higher permeability of the mucosal
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membrane compared to that of the cornea [8].
Corneal permeability of the drug is low for ophthalmic solutions administered
topically. The human cornea has 5 tissues with 3 of them, the epithelium, the
endothelium, .and the inner stroma being the main barriers to absorption. The epithelium
is relatively lipophilic and has low porosity and high tortuosity, which makes it the main
barrier for hydrophilic drugs. The middle stromal layer, which consists mainly of water
interspersed with collagen fibrils and accounts for most of cornea's thickness, is the main
barrier for lipophilic drugs [5,9-11]. All these barriers result not only in low penetration
of the drug but in systemic side effects of the ophthalmic drugs with topical

I
I
I
~
~

administration [12-13].
An ideal ophthalmic solution will provide deep penetration beyond the initial
layers of the eye. Consequently this can only be achieved by sustained drug release and
the ability to remain in the vicinity a front of the eye for a long period of time.
The raw materials used in ophthalmic solutions must be of the highest quality
available and each lot of the ingredients must be qualified against multiple
pharmacopoeia specifications prior to its use, in order to be safe and to meet global
requirements. Also, each ingredient has a specific function in the formulation. Some
general characteristics of ingredients that must be studied are concentration, tonicity,
viscosity and pH adjustment (buffer solutions), active ingredient stabilizers, and
component solubility. Selection of all the formulation components is done based on the
physical and chemical compatibility between them and biocompatibility with delicate
ocular tissue.
The pH and buffering of ophthalmic solutions is very important to product
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stability and product quality in general. Ideally an ophthalmic solution would be buffered
at pH 7.4, which is the pH of tear fluid. In addition to formulation stability, pH
adjustment enhances comfort, safety, and activity of the product. The pH of ophthalmic
solutions is usually buffered within a range to provide maximum product stability and
shelf life of about two years. The pH value expected to be maintained within the range
during the entire shelf life of the product. An optimal pH range for ophthalmic
formulations is between 7.0-7.4 and usually phosphate buffer is selected as a starting
point.
Well buffered solutions prevent unwanted changes in pH due to hydroxyl ion
release from the glass bottles in which solutions are stored. Unwanted pH changes can
create discomfort to the patient especially for changes outside the tolerable pH range
(6.6-8.5) of the cornea. Larger pH changes, outside the pH range of 4 to 10 will create
permeability changes.
Precipitation and deterioration of the drug can occur after administration for
formulations with pH that is not close to physiological pH of tears. The introduction of
any formulation into the eye that causes discomfort due to precipitation is likely to
stimulate tear production and increase the rate of drug removal from the eye making such
formulations unsuitable for their intended use.
Sterility is of high importance and every ophthalmic solution must be
manufactured under conditions to render it sterile in its final package and for the shelf life
of its product. Each lot of product should be tested and released with appropriate
pharmacopoeia methods to verify product sterility. There are different methods (steam,
dry-heat, gas, ionizing radiation, filtration and aseptic processing) of sterilization of
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ophthalmic solutions and selection of the method is done based on the compatibility of
active components with other ingredients in the formulation.

To reduce the biggest

source of microbial contamination, only sterile purified water should be used preparing
ophthalmic solutions.
Clarity is one of the ophthalmic solution properties, as by definition solutions are
expected to be free of foreign mater and undissolved material. It is a critical parameter, so
samples are tested to verify that they are free of foreign matter. Clarity is enhanced by
filtration and it is essential that this is performed by equipment that is clean and does not

!

I
j

j

j
i
j

I
I

contribute to contamination of the formulation. The overall process can be done in a
combined step with sterilization and must take place in a clean environment. Solutions
that fail the clarity test should not be used for instillation to the eye due to product
instability and possible discomfort to the eye which will stimulate tear production and
. drug removal.
Tonicity is a measure of the osmotic pressure of two solutions separated by
semipermeable membrane [14]. It is important to the eye that ophthalmic solutions
should be adjusted for correct tonicity. When the concentration of the solute is higher
outside the membrane (cell membrane) the solution is hypertonic, when the concentration
of the solute is lower outside the membrane the solution is hypotonic and when the
concentration is the same in both sides of the membrane the solution is isotonic [15]
Depending on the drug and its intended use, solutions can be prepared with
different tonicity. The external part of the eye is more tolerant to tonicity variations. An
isotonic solution is more important for intraocular use. However, in some cases of dry
eye, tear fluid is reported to be hypertonic and a hypotonic artificial product is used to
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balance this condition. Common ingredients used for the tonicity adjustment of the
ophthalmic solutions are sodium chloride, potassium chloride, manitol, dextrose,
propylene glycol, and glycerine.
There are three additional areas very important to ophthalmic formulations:
preservation, demulcents, and active components. These are discussed extensively in the
next chapters. In these chapters the importance of preservatives in ophthalmic solutions
was discussed and one of the most widely used preservative systems (benzalkonium
chloride) in over the counter ophthalmic solutions was studied. Two chapters will focus
on the study of demulcents or lubricants in ophthalmic solutions. Demulcents in over the
counter ophthalmic solutions have a dual role, to control viscosity and offer pain relief in
irritated mucous membranes. Polyvinylpyrrolidone. PEG400 and glycerin are the three
demulcents which were studied in the following chapters. Vasoconstrictors are one of
the major areas of active components in ophthalmic solutions. They are used primarily
for the treatment of redness and minor irritations in the eye. One of the vasoconstrictors
used in ophthalmic solutions is oxymetazoline and it is member of other vasoconstrictors
that have similar chemical structure and exhibit the same degradation profile.
Oxymetazoline and its known degradant were studied in the next chapters.
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Chapter 2: Preservatives

2.1 Introduction

Preservatives are chemical substances that are used in ophthalmic solutions to
preserve the integrity of the solution by killing microbes or inhibiting microbial growth,
thus extending the product shelf life. This is extremely important given the environment
in which these solutions are kept and in that how they are often mishandled. Solutions
kept in medicine cabinets, purses, and pockets, exposed in extreme conditions of heat,
humidity, provide a good environment for microbial growth. Often, users mishandle
multidose bottles by touching the tip of the dropper with their fingers or with their eyes,
introducing contamination. There are several types of preservatives within two major
classifications, but only a few are applicable in ophthalmic solutions. Preservatives are
classified in two major categories, antioxidants and antimicrobial. Antioxidants are
inhibit oxidation reactions that disrupt the cell metabolism. Antimicrobial preservatives
kill or inhibit the growth of microbes introduced during manufacturing or usage. The
most commonly used preservative in ophthalmic solutions is benzalkonium chloride,
which kills microorganisms by disrupting cell membranes.
Surfactants are also a major area of preservatives within the antimicrobial
category. They are classified as cationic, anionic, nonanionic and amphoteric based on
their net charge in solution and chemical structure. When dissolved in water surfactants
reduce the surface tension between the liquid/vapor surface or at the water/oil interface.
Cationic surfactants ionize in aqueous solution to produce positively charged organic ions
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that are responsible for surface activity. Cationic surfactants are widely used in
ophthalmic formulations' because of their low toxicity, high surface activity, aqueous
solubility, and their high preservative efficacy that often reduces or eliminate the need for
additional preservatives. Benzalkonium chloride preservative efficacy is well established
and it is widely used in ophthalmic solutions. Its physical attributes of high water
solubility, and lack of color or odor in solution makes the BAC quaternary ammonium
salt suitable as a preservative in ophthalmic solutions.
Benzalkonium chloride (BAC) is a mixture of alkylbenzyl dimethylammonium
chlorides of various alkyl chain lengths with a general formula: [C6HsCH2N(CH3hR]Cl,
in which R represents a mixture of alkyls with n-C 12 H25, n-C J4 H29, and n-CJ6H33
comprising the major portion of the BAC. The chemical structure of benzalkonium
chloride is presented in Figure 1. It is commonly used as an antiseptic with the greatest
activity associated with the C J2-C 14 alkyl derivatives.
Benzalkonium chloride has been in clinical use since 1935 and is an active
ingredient in a wide variety of prescription and over-the-counter products. Is generally
found in topical solutions for cleaning, minor wound care and disinfecting in 1:750
dilution with water, or about 0.133%. For major wound care, mucous membrane and
ophthalmic applications, concentrations are usually 10-50 times lower. BAC is one of the
typical preservative systems used in ophthalmic solutions [16-17]. Is more active against
bacteria but is weak against mold and is more active above a pH of 6 [18]. The
homologues do not posses identical bactericidal activity. In general, the C I2 homologue is
most effective against yeast and fungi, the C J4 homologue against gram-positive bacteria,
and the C 16 homologue against gram-negative bacteria [19-20].
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n 8, 10, 12, 14, 16, 18

Figure 1: Chemical structure of benzalkonium chloride (BAC), with "n" representing different alkyl chain
lengths_ Major portion of the BAC comprising by a mixture of alkyl chains with length of n-C I2 , n-C I4 , and

C16
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Recently, benzalkonium chloride was proven to enhance the antibacterial efficacy
of antibiotics such as gatifloxacin [21]. Many analytical methods (HPLC and HPCE)
were developed to determine BAC in a variety of products [16, 19-20, 22-26]. However,
the described methods did not examine the fast separation of BAC homologues and their
applicability might limited to a specific ophthalmic solutions. In some instances, due to
the low conj:entrations of BAC, a salting-out technique was employed with the sum of all
the homologues that might be present [16].
In this work we describe a new method for the analysis of the benzalkonium
chloride in ophthalmic solutions. This represents an improvement over the current USP
method for total BAC, which involves a titration [27]. The new method is a stability
indicating method, its applicability was tested in different ophthalmic solutions and
successfully validated based on International Conference on Harmonization guidelines
[28].

2.2 Experimental

2.2.1 Reagents and Chemicals
The raw material for BAC (Century Pharmaceuticals, Indianapolis, USA) was
provided by the product development group. ACS reagent sodium acetate trihydrate and
reagent grade glacial acetic acid were purchased from Sigma Aldrich (Saint Louis,
Missouri, USA). HPLC grade methanol was purchased by J.T. Baker (Phillipsburg, NJ,
USA).
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2.2.2 Equipment

The Waters Alliance HPLC system (Waters Corporation, Milford, Massachusetts,
USA) was used for the method development and method validation. The Alliance liquid
chromatography system was equipped with 2695 separation module, 2487 UV detector
and 996 photo diode array detector. Data collection and processing was done using the
Empower chromatographic data acquisition system.

2.2.3 Chromatographic Conditions

A simple isocratic high performance liquid chromatography (HPLC) method was
developed for the determination of benzalkonium chloride (BAC) in ophthalmic solutions.
The chromatographic column used was a YMC, CN, 5 Ilm, 150 mm x 4.6 mm. The flow
was kept at 1.0 mUmin during the length of the run and the column temperature was
40°C. The wavelength was 262 nm and the injection volume was 100 ilL. The mobile
phase utilized was 35:65 of 0.075 M sodium acetate trihydrate buffer with pH value
adjusted to 5.0 with acetic acid: methanol.

2.2.4 Testing Parameters

Testing of the chromatographic method was performed in accordance to
International Conference on Harmonisation (ICH) guidelines [28J and typical operating
procedures for pharmaceutical analysis. The test parameters will be discussed in the same
order as they were investigated during the method validation.
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2.2.4.1 Specificity
The specificity is the ability of the method to measure accurately and specifically
the analytes in the presence of components that may be present in the sample matrix. In
order to measure the degree of interference, ophthalmic samples, placebos, and standards
of BAC were exposed to stress conditions of acid, base, peroxide, light and heat.
Subsequently, the solutions were analyzed according to the chromatographic parameters
presented in this paper to ensure no extraneous peak coeluted with the multicomponent
BAC peaks. A UV diode array detector was used to check a 3-dimensional spectrum.

2.2.4.2 Accuracy
In order to measure the exactness of the analytical method between the true value
and an accepted reference value, we spiked an ophthalmic solution without benzalkonium
chloride (BAC) with BAC standard at three working levels 70%, 100%, and 130% of the
theoretical concentration. Six preparations were performed at each level and assayed as
per method conditions. The average result from each individual level was compared to its
respective theoretical concentration value to check for any potential bias. All three
average values were not significantly lower or higher than the theoretical value e.g.
±1.5%.

2.2.4.3 Linearity
In order to show that there is a direct proportional relationship between the
analyte response and its concentration, five concentration level solutions of BAC,
corresponding from 50-150% of theoretical concentration were prepared and injected. In
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addition, the ability of the system to retain and carryover the analyte into subsequent
injections was evaluated by injecting a blank solution (diluent only) in duplicate
immediately after the 150% linearity level.

2.2.4.4 System Peiformance \
In order to ensure performance of the system before and during the analysis,
system performance parameters, as defined in USPINF, [29] were established as a direct
result of ruggedness and robustness experiments.

2.2.4.5 Precision
2.2.4.5.1 System Precision: We determined the system precision using six replicate
measurements of a 100% theoretical standard solution containing benzalkonium chloride.
The error contributed by the system, independent of the sample preparation, should be
less than the acceptance criteria of 2.0 %.
2.2.4.5.2 Repeatability: The repeatability, which is the error contributed by sample
preparation, was determined by six identical sample preparations of the same sample.
2.2.4.5.3 Intermediate: In order to evaluate the degree of agreement among test results
obtained from multiple samplings of the same lot of samples on a different day using
different instrument, column and analyst, six identical sample preparations of the same
sample were used.
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2.2.4.6 Robustness
2.2.4.6.1 Chromatographic parameters: Robustness of a method is a measure of its
capacity to remain unaffected by small but deliberate variations in chromatographic
parameters. The parameters under test were wavelength, flow, colul!ln temperature,
mobile phase ratio, and pH of the buffer in the mobile phase. These parameters were
changed one at a time. System suitability and samples run were conducted with
unchanged method parameters and modified parameters.
2.2.4.6.2 Solution Stability: Standard and sample solutions were stored at room
temperature and tested at initial, 48 hrs and 144 hrs. The solutions were tested against a
freshly prepared standard at each time point.

2.3 Results and Discussion

2.3.1 Developmental Work
There are many factors to consider when developing methods. One of the factors
is the choice of the proper detection scheme which depends on the analyte's properties.
UV detection was selected since benzalkonium chloride has an intense chromophore
absorbing in the UV. The selection of the wavelength in our method (A=262 nm) was
made based on a second maximum absorbance of BAC. More specific benzalkonium
chloride has two UV maxima at about 210 nm and 262 nm. The second maximum is
weaker but serves well with the selected mobile phase of methanol : sodium acetate
trihydrate (65:35) since baseline noise was observed at wavelength around 210 nm. In
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addition, the 262 nm wavelength was selected because methanol has a cutoff wavelength
of 205 nm.
Ideally for method development of new compounds with reversed phase HPLC
several columns should be screened based on the pH tolerance. However, BAC is a
mixture of well defined molecules and for that reason only one column was used during
the method development. Different HPLC methods were reported in the literature for the
analysis of benzalkonium chloride using reversed phase chromatography [30-34]. Due to
its multicomponentnature and its low concentration in ophthalmic solutions (50-100
ppm), BAC is a difficult material to analyze. The method should be quantitative. and
qualitative in order to identify and distinguish the homologue components from each
other and from other excipients. As a result, due to the low concentration of BAC and
the fact that different formulations contain different sources of raw material which have
different homo10gues made the method development very challenging.

Several

formulations with different homologues and different amounts of BAC were obtained and
analyzed with the current method. The method appears to be suitable for these types of
formulations. Figure 2 shows an overlay chromatogram of several different ophthalmic
formulations containing the Cu, C I4, C l 6 and small amount of CIS BAC homologues.
In the isocratic method, constant eluent composition in the column implies that

equilibrium was established in the column and components moving through the column
with constant velocity. Many attempts were made to elute all BAC homologues with
gradient mobile phases but poor resolution between the BAC homologues and poor
applicability between: different formulations made the method impractical.
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Figure 2: Overlay chromatogram of several different ophthalmic formulations that contain C l6 and CIS of
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Since benzalkonium chloride is known for its adsorption in membrane material [17], a
filter membrane (PTFE) was tested from two different vendors to evaluate the need of
filtering solutions during the sample preparation. PTFE filters with dimensions of 25 mm
and 0.45 !-tm porosity were tested. Results were compared against a non filtered sample.
No significant change was observed between the vendors and filtered vs. unfiltered
samples.
System performance parameters were selected to provide confidence that the
method is capable of determining BAC in ophthalmic solutions. A typical chromatogram
for the benzalkonium chloride system performance standard solution is shown in Figure 3.
The selected parameters include injection precision, resolution between C 12 , C l4 and C 14,

C16 homologues (when applicable), and a tailing factor of BAC homologues (CI2, C 14,
C I6). In addition, check standard conformity and bracketing standard conformity were
proved during each chromatographic run.

2.3.2 Experimental Work
The specificity of the method was tested and no interference was observed for the

. BAC peaks from forced degradation samples and ophthalmic solutions without BAC.
During these studies equivalent amounts as per method of ophthalmic solution samples
with and without BAC, BAC standard were stressed for the following conditions: (1) heat
at 7SOC for 1 hr; (2) 5 mL of 1 N hydrochloric acid at 75°C for 1 hr; (3) 5 mL of 1 N
sodium hydroxide at 75°C for 1 hr; (4) 5 mL of 30% hydrogen peroxide at 75°C for I hr;
and (5) light exposure for 24 hrs as per ICH option 1.
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(a)

(b)

Figure 3: System performance chromatogram (a): Full scale chromatogram (b): Expanded chromatogram.
Performance parameters such as injection precision, resolution between the homologues, and tailing factor
are evaluated.
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Target
Concentration
Level
20%

Concentration

Response

(pg/mL)

(Area)

50%

9.95
24.88

58175.46
149170.44

100%

49.77

296918.96

120%

59.72

359065.31

160%

79.62

480266.94

Slope

6047756.17

Y Intercept (% )

-2147.48

Correlation

0.99995

Table 1: Linearity parameters of benzalkonium chloride. Benzalkonium chloride found to have a linear
response over a range of 20%-160% of theoretical concentration 0.05 mg/mL.
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The repeatability of the method was evaluated by

SIX

identical sample

preparations of a homogeneous batch and the results were found to be within the
specifications. The percent relative standard deviation of the six preparations for BAC
was found to be 0.7%.
In order to further validate our results, the experiment was conducted again on

different day by a different analyst, using different instruments, and different columns.
The experimental mean agreement between the two experiments was found to be 0.4,
both experimental results were within the acceptance criteria. Results are displayed on
Table 2b.
The accuracy of the method was established by assaying three different BAC
concentration levels 70%, 100%, and 130% of the theoretical concentration (0.05mglmL).
Six preparations of ophthalmic solutions without benzalkonium chloride, at each level,

.l

were spiked with standard BAC and injected into the HPLC system. Results are reported

i

in Table 2c with BAC mean recovery values varied from 99.2 to 99.5 % LC. No bias was

I

observed for BAC, since the results for the mean recovery from all three accuracy levels
were not significantly lower or higher (±1.5%) than the theoretical value. The range in
which the method is shown to be linear and accurate for benzalkonium chloride is
between 70-130% of theoretical concentration (0.05 mg/mL).
The

method

remained

unaffected

by

small,

deliberate

variations

in

chromatographic parameters and mobile phase preparation. The parameters tested were
wavelength, flow, temperature, mobile phase ratio, and pH of the buffer. Table 3 shows
the results of the small deliberately variations of the method conditions.

1
,

l
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Replicate #

Peak Response (Area)
302895.88
296933.32
298289.29
298556.27
298255.89
298355.70
298881.06
0.7

1
2
3

4
5
6
Mean
%RSD
(a)

Replicate
1
2
3
4
5
6
Mean
%RSD
Mean Agreement

% Label Claim (O/OLC)
Benzalkonium Chloride
Experiment 1
Experiment 2
100.4
99.5
101.0
101.3
101.2
100.3
99.5
101.6
100.8
100.8
101.5
101.8
100.6
101.0
0.6
0.8
0.4
(b)

Preparation #

1
2
3
4
5
6
Mean
O/ORSD

BAC
Mean Recovery Value %LC
100% Level
70% Level
130% Level
99.4
99.4
98.9
99.2
99.1
99.3
99.4
99.6
99.2
99.6
99.4
99.3
99.7
99.7
99.1
100.1
99.4
98.9
99.4
99.2
99.5
0.3
0.3
0.2
(c)

Table 2: Experimental data of (a) System precision results, (b) Intermediate method precision results, (c)
Accuracy results (ophthalmic solution spiked with BAC at three levels, 70, 100, 130% of theoretical)
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Parameter
Changed
No Change (65:35), pH-5.0

Percent
Difference
N/A

Comment
(%LC)
98.5

Wavelength 260 nm

0.5

99.0

Wavelength 264 nm

0.4

98.9

Column Temperature 38°C

0.3

98.8

Column Temperature 42 °C

0.7

99.2

Flow 0.9 mLlmin

1.1

99.6

Flow 1.1 mUmin

1.3

99.8

• Mobile phase ratio (60:40), pH-5.0

1.4

99.9

Mobile phase ratio (70:30), pH-5.0

0.7

99.2

Mobile phase pH:4.8, (65:35)

0.7

99.2

Mobile phase pH=5.2, (65:35)

0.4

98.9

i

i

I

i

i

i

I

Table 3: Robustness results. Parameters which evaluated were wavelength, flow, column, mobile phase
ratio and mobile phase pH.
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The robustness results were within acceptance criteria of ±3.0 %LC, however some
parameters are more critical than others. More specific the mobile phase ratio at 60:40 is
critical to the shape of the BAC homologues and tailing factor (T f) did not meet
suitability criteria as per the method. The results variations that were observed between
the normal method conditions and the changed parameters were from 0.3% to 1.4%.
Critical parameters of the method such as mobile phase ratio, pH, and buffer
concentration were evaluated and the results followed normal trends for reversed phase
chromatography for cationic compounds. Figure 6 shows overlay chromatograms of
mobile phase ratio, pH and buffer concentration.
The stability of the standard and sample solutions for BAC was evaluated. The
results are displayed on Table 4 and show no significant decrease over a period of 240 hrs
for BAC in standard and 72 hrs for BAC in sample.
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Figure 6: Robustness overlay chromatograms of critical method parameters: (a): organic:buffer ratio
(b): pH and (C): buffer concentration
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Time Point

Benzalkonium Chloride in Standard
Response

% Difference from Initial

Initial

100.0

N/A

24 Hours

100.7

0.7

72 Hours

101.9

1.9

144 Hours

102.0

2.0

Benzalkonium Chloride in Sample

Time Point

Response

% Difference from Initial

Initial

96.8

N/A

24 Hours

97.6

0.8

48 Hours

98.6

1.8

1
j

Table 4: Solution stability results for BAC in standard and sample solutions. Standard solution was stable
over a period of six days and sample solution was stable over a period of two days.
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2.4 Conclusion
The importance of preservatives in over the counter ophthalmic solutions is well
known given the environment in which these solutions are kept. Often, users store the
multidose bottles in medicine cabinets. purses, and pockets. exposed to extreme
conditions of heat and humidity, all of which provide a good environment for microbial
growth. Benzalkonium chloride is by far the preservative system of choice in ophthalmic
solutions. In this chapter a new method for the determination of total benzalkonium
chloride in ophthalmic solutions is described. The method separates the BAC
homologues from each other and from other formulation components. The homologue
separation is dependent to mobile phase ratio, pH and buffer strength. The testing for this
method was performed according to ICH guidelines and met all acceptance criteria. Our
experimental results indicated that the method is precise, accurate, and linear at
concentration ranges of 0.035 mg/mL to 0.065 mglmL for total BAC. The analytical
procedure is simple. fast, isocratic based on reversed phase chromatography (RPC) and
applicable to a variety of ophthalmic solutions with BAC from different vendors.
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Chapter 3: Demulcents (Polyvinylpyrrolidone)

3.1 Introduction
Lubricants, or demulcents, are often present in ophthalmic solutions and are used
to control the solution viscosity. Additionally, they offer a medicinal benefit, relieving
pain in inflamed or irritated mucous membranes. There are several demulcents in use in
ophthalmic solutions, with selection done based on excipient compatibility, viscosity and
the intent of medicinal benefit. In this study, several demulcents were studied:
polyvinylpyrrolidone (PVP) , polyethylene glycol-400 (PEG-400) and glycerin. Since
PVP and PEG400 are polymeric, size exclusion chromatography (SEC) is the technique
of choice, however, most SEC methods focus on molecular weight characterization rather
than quantitative analysis. In this work, total PVP in ophthalmic solutions was
determined using the unusual combination of size exclusion chromatography, ultraviolet
visible detection and quantitation of an analyte peak that elutes before the void volume
disturbance [35]. A more conventional size exclusion chromatography method was used
for the simultaneous determination of PEG400 and glycerin in ophthalmic solutions,
using size exclusion chromatography, with refractive index detection [36], described in
Chapter 4.
Povidone (Polyvinylpyrrolidone, PVP) is a chain polymer of I-vinyl-2
pyrrolidone, developed in the late 1930's [37]. PVP is obtained by a multistep synthesis
that concludes by polymerization of vinylpyrrolidone in aqueous solution in the presence
of hydrogen peroxide [38]. A wide range of molecular weights, from a few thousand to a
few million Daltons can be obtained by controlling the degree of polymerization. PVP is
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a white hygroscopic powder and unlike many synthetic polymers is soluble in a variety of
traditional solvents such as water, chlorinated hydrocarbons, alcohols, arnides, and
amines [39]. In our studies, PVP with a molecular weight of about 50,000 with a K-value
of 30, typical in ophthalmic solutions, were used [40]. Figure 7 shows the structure of
polyvinylpyrrolidone.
PVP originally was used as a plasma substitute and in a variety of applications. Its
hygroscopic properties, film formation, and adhesion to different materials have made
PVP widely used in pharmaceuticals, cosmetics and industrial production. The
interactions between the carbonyl groups in PVP and the hydroxyl group in polyphenols
are well known and have been reported in the literature. Due to these interactions PVP is
used to isolate polyphenols and as a colloidal stabilizer in beers by selective removal of
tannoid polyphenols [41-42], PVP formulations have been used to produce desired
solution viscosity, allowing the deposition of a uniform coating thickness of a photoresist
in the manufacture of high resolution display screens [43]. In ophthalmic solutions, PVP
is used as a demulcent or moisturizer and is generally present at approximately 1%
concentration in an aqueous matrix also containing other excipients and active
formulation components. It has been shown in combination with polyethylene glycol 400
and dextran 70 to be effective for the temporary relief of minor irritations, for protection
of the eye against further irritation from the wind or sun and relief from eye dryness [44].
Many chromatographic methods have been reported in the literature for the
determination of PVP, either qualitative determination of the molecular weight range of
the polymer or quantitative determination in formulations and products, with most
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IUPAC name: Polyvinylpyrrolidone
Molecular formula: (C6H9NO)n
Formula weight: 35000-51000

Figure 7: Structure of polyvinylpyrrolidone
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focusing on the qualitative aspects such as the form of polyvinylpyrrolidone present and
whether materials with same K-value are structurally the same [45-46J,
A variety of capillary electrophoresis (CE) methods for the characterization and
determination of povidone have been reported, including capillary zone electrophoresis
(CZE) and capillary gel electrophoresis (CGE) [47-50]. Polyvinylpyrrolidone has been
determined in several pharmaceutical matrices with solid phase microextraction and GC.
The fibers were polypyrrole (PPy) and desorption was performed at the inlet of gas
chromatograph equipped with a nitrogen phosphorous detector [51J. PVP has also been
used as stationary phase materials or extractant [52-55]. SEC determinations of
polyvinylpyrrolidone have focused on molecular weight characterization of the
polyvinylpyrrolidone itself or the use of polyvinylpyrrolidone as a molecular weight
calibrator for other determinations [56-64],
SEC is not usually used in combination with UV detection, however it is clearly
applicable if the analytes and other compounds of interest in the analytical samples
contain a chromophore. Some pharmaceutical applications of SEC with UV detection
include a recent study of the mass balance in the oxidative degradation of rapamycin and
the analysis of various proteins and biological polymers in formulations [65-67].
Determination of total PVP present in the matrix of a pharmaceutical formulation using
SEC and UV detection has not been previously reported. In this work we describe a fast,
straightforward new HPLC method for the analysis of total PVP in ophthalmic solutions.
The new method is stability indicating and was successfully validated based on the
International Conference on Harmonization guidelines for pharmaceutical quality
assurance [68],
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3.2 Experimental

3.2.1 Reagents and Chemicals

The raw material for PVP was purchased from BASF AG (Ludwigshafen,
Germany). HPLC grade methanol was obtained from Fisher Scientific Inc. (Fairlawn,
New Jersey, USA). ACS reagent grade sodium acetate was purchased from Sigma
Aldrich (Saint Louis, Missouri, USA). Water was obtained using a Milli-Q (Millipore,
Milford, MA) purification system located in our laboratory.
Laboratory formulations of typical opthalmic solutions were prepared in water at

0.5 mg/mL concentration of povidone. There were diluted by adding 10 mL of
formulation to a 50 mL volumetric flask and diluting to the mark with water prior to
HPLC analysis. The final working concentration of the sample and standard solutions
was 0.1 mg/mL.

3.2.2 Instrumental Conditions

An Alliance HPLC system equipped with a 2695 separation module with 2487
UV and 996 photodiode array detectors was used for all experiments. Data collection
and processing was performed using an Empower chromatographic data acquisition
system.

(Waters Corporation, Milford, Massachusetts, USA)

The chromatographic

column was a TSKgel G1000PW, 7.5 mm ID x 30 cm, 12 !lm column (TOSOH
Bioscience, Tokyo, Japan). The flow was kept at 1.0 mLimin during the length of the run
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and the column temperature was 50°C. The UV detector wavelength was 220 nm and the
injection volume was 25 JlL. The mobile phase was premixed 800 mL 0.1 M sodium
acetate and 200 mL methanol generating a mobile phase pH of about 10.

3.2.3 Testing Parameters

Testing of the chromatographic method was performed in accordance with ICH
guidelines and typical operating procedures for pharmaceutical analysis. The test
parameters are presented in the same order as they were investigated during the method
validation. Specificity was determined by exposing ophthalmic solution samples with and
without polyvinylpyrrolidone, and polyvinylpyrrolidone standards to stress conditions of
acid, base, hydrogen peroxide, light and heat and subsequently analyzing them according
to the method. A photodiode array detector was used during validation to ensure that no
interfering compounds co-eluted with PVP but is not necessary for the final method.
Accuracy was measured by spiking with PVP ophthalmic solutions without PVP at three
working levels 0.35, 0.50 and 0.80 mg/mL (70%, 100%, and 130% of the standard
concentration). Six preparations were performed at each level and assayed as per method
conditions. The average result from each individual level was compared to its respective
theoretical concentration value to check for any potential bias.
To ensure that the method is linear in the working concentration range, five
concentration level solutions of polyvinylpyrrolidone, corresponding from 0.25-0.75
mglmL (50-150% of the expected analyte concentration) were prepared and injected. In
addition, the ability of the system to retain and carryover the analyte into subsequent
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injections were evaluated by injecting a blank solution (diluent only) in duplicate
immediately after the 150% linearity level. To ensure performance of the system before
and during the analysis, system performance parameters, as defined in the USPINF, were
established as a direct result of ruggedness and robustness experiments [69].
System precision was determined using six replicate measurements of a 100%
theoretical concentration standard solution (0.5 mg/mL PVP concentration) containing
polyvinylpyrrolidone, with an acceptance criterion of the RSD being less than 2.0%.
Repeatability was determined by six identical sample preparations of the same lot. To
determine agreement among test results obtained from multiple samplings of the same lot
of samples on different days using different instruments, columns and analysts, six
identical samples from the same lot were prepared and analyzed.
Robustness was determined by examining small variations in: wavelength (±4
nm), flow rate (±0.1 mUmin), column temperature (±5°C), and mobile phase preparation
(±1O%). These parameters were changed one at a time. System performance and sample
runs were both conducted with unchanged method parameters and modified parameters.

In addition a quantitative comparison study was performed between the raw material that
was used to prepare the batch and other raw materials of polyvinylpyrrolidone including
a USP reference standard. One sample preparation was run and quantitated with five
different standards as per the method. Further, to assess sample stability, standard and
sample solutions were stored at room temperature and tested at initial, 24 hrs, 96 hrs, and
192 hrs. The solutions were tested against a freshly prepared standard at each time point.
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3.3 Results and Discussion

3.3.1 Developmental Work

The physical and chemical properties of polyvinylpyrrolidone have been well
established, since its discovery in 1930 [37-40]. UV detection was selected for this work
since PVP has a chromophore in the ultraviolet range, with a maximum at 213.5 nm. The
UV spectrum of PVP is shown in Figure 8. In the final method, 220 nm was selected for
the UV detector wavelength. During method development. excessive noise. possibly
from the solvent (methanol has a UV cutoff of 205 nm) or impurities in the solvents
precluded the use of 213.5 nm. No deleterious quantitative effects from detecting PVP
on the slope of the UV spectrum rather than the maximum were observed. Although the
UV detector is possibly the most versatile and useful detector in high performance liquid
chromatography, it is not as widely used in SEC since many polymers do not absorb
electromagnetic radiation in the UV range.

Other detectors such as refractive index or

light scattering are more commonly used, but quantitation and method validation are
often challenging with these [70]. Thus the combination of SEC with UV detection is
especially suited to this application and would be suitable for other polymer analysis in
which a chromophore is present. Figure 8 shows a UV spectrum of povidone with a
maximum absorbance about 213 nm.
The main goal during method development was to have an isocratic method that
separates PVP from other compounds in the formulation or degradation products.
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Figure 8: UV spectrum of polyvinylpyrrolidone with a UV maximum absorbance at 213 nm.
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Usually in SEC method development for unknowns, the molecular weight of the analyte
polymer must be independently determined to aid in column selection. In this study that
was not necessary since the molecular weight range of PVP, approximately 50 kDa, was
provided by the vendor.

Initially, several size exclusion columns from different

manufacturers were screened and TSK-gel GlO00PW, 7.5 mm ID x 30 cm x 12; !!m
column was selected based on symmetrical peak: shape of PVP. TSK-gel columns in
general consist of hydrophilic polymethacrylate spherical beads with sizes ranging from
12 !!m to 17 !!m. These types of columns are suitable for the analysis of water soluble
polymers and more specific the Gl000PW is suitable for small (1000 Da and less)
molecular weight polymers. As seen in Figure 9, in our method the TSK-ge1 G lOOOPW
column is used in a reversed context: the analyte is of much higher molecular weight than
would normally be separated by this column, eluting before the void volume disturbance,
fully excluded from the stationary phase.

Other compounds present, with molecular

weights less than 1000, elute in the separation range of the column. While uncommon,
quantifying a peak: eluting before the void volume has been recently reported in a similar
context for the group assay of polyvinylsulfonic acid impurities in 2-(Nomorpholino)
ethanesulfonic acid [71]. Figure 9 clearly shows a very symmetrical peak: for PVP,
demonstrating a satisfactory tailing factor for system performance and the validation data
presented in the next section demonstrate adequate precision. The symmetrical peak: of
polyvinylpyrrolidone is expected based on the exclusion of the molecule from the porous
space of packing material and its fast elution from the column.
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(b)

(a)

Figure 9: Chromatogram of polyvinylpyrrolidone (a): Full scale chromatogram (b): Expanded
chromatogram
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SEC separation is based on molecular size of the analyte relative to the pore size
of the packing material. Mobile phase selection is important to avoid enthalpic
interactions between the analyte and the packing material. There are a variety of solvents
compatible with TSK-GEL columns, so the selection process depends on the chemical
structure and ionic nature of the analyte. In this study since a UV detector was used the
ideal mobile phase should have a low UV absorbance as well. Methanol has a low
wavelength UV absorbance cutoff of about 205 nm and low background absorbance
combined with good solubilizing properties for polyvinylpyrrolidone made methanol the
organic solvent of choice for this method. For simplicity, premixed aqueous buffer
mixture of 0.1 M sodium acetate with methanol (80:20% v:v) was selected as the mobile
phase [72]. This generates a mobile phase pH of approximately 10, which assists in
ensuring rapid and efficient transport of PVP through the column by ensuring that the
electron pair on nitrogen in PVP does not protonate while the hydroxyl groups on the
surface of the TSK-GEL column are slightly deprotonated, generating additional
repulsion between the stationary phase and the analyte.
Temperature

adjustment

can

reduce

the

analysis

time

and

improve

chromatographic performance. More specific as the temperature increases, the viscosity
of the mobile phase decreases and the diffusivity of the analyte increases. Fast size
exclusion chromatography has been discussed in the literature and temperature is one of
the primary parameters adjusted to achieve faster analysis times [73-74]. Optimum
chromatographic performance was obtained in this method with column temperature at
50°C.
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3.3.2 Experimental Work

Figure 10 shows the analysis of PVP in a formulation (top), standard (middle) and
formulation without PVP (bottom). PVP does not appear in the placebo which is simply
a formulation prepared without the analyte, demonstrating that compounds other
compounds that commonly appear in ophthalmic formulations will not interfere with the
method. This chromatogram clearly demonstrates the reverse SEC analysis: determining
a larger molecular weight compound using a column designed for small molecular weight
analytes. PVP elutes first, followed by the void volume disturbance, followed by other
components. In each case, chromatographic performance, was evaluated by tailing factor,
peak shape, peak width, and found to be adequate.
Figure lla shows chromatograms of several PVP polymer formulations in
combination with a vinyl pyrollidone monomer.

In these chromatograms, the PVP

polymer is seen eluting before the void volume of the column (totally excluded from the
stationary phase pores) and the monomer eluting within the analytical range of the
column. Further, all of the polymer formulations elute at the same retention time in the
void volume, providing the desired total analysis from a single chromatographic peak,
regardless of variations in the polymer formulation.

Essentially all material with a

molecular weight greater than 1000 Da is included in the main peak. In Figure lIb, a
chromatogram of the PVP used in this study for ophthalmic formulations in combination
with its monomer is shown, demonstrating the outstanding selectivity of this system.
The specificity of the method was tested and no interference was observed for the
polyvinylpyrrolidone peak from ophthalmic solution without polyvinylpyrrolidone and
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Figure 10: Overlay chromatogram of ophthalmic formulation (top), standard of polyvinylpyrrolidone
(middle), and formulation without polyvinylpyrrolidone (bottom)
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Figure 11: Overlay chromatogram of different molecular weight polyvinylpyrrolidone polymers (a)
chromatogram of polyvinylpyrrolidone and its monomer
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forced degradation samP.1es. To ensure no extraneous peak co-eluted with the peak of
interest, a UV diode array detector was used to double check the full UV spectrum for all
peaks.

Figure

12

shows

overlay

chromatograms

of the

sample

without

polyvinylpyrrolidone (a) sample (b) and standard (c) at different stress conditions.
Linearity of the method was established by injecting five standard concentrations
of polyvinylpyrrolidone and preparing a calibration curve by plotting PVP response
versus concentration. The solutions covered a concentration range of 0.05 - 0.15%. The
linearity curve for polyvinylpyrrolidone is presented in Figure 13. The solutions covered
a range of 50%-150 % of theoretical concentration 0.1 mg/mL. The method was linear in
this range with R2 values of 0.9999. Concentration of linearity solutions, responses and
linearity parameters such as slope, y-intercept, and coefficient of determination are listed
in Table 5. No carryover was observed into blank injections immediately after the highest
level linearity standard, ensuring independence of the samples.
System precision was established by six replicate measurements of a 100%
theoretical standard solution of povidone. The %RSD for povidone was found to be 0.1 %.
Table 6a shows the results, mean and standard deviation.
The repeatability of the method was evaluated by six identical sample
preparations of a homogeneous batch and the results were found to be within the
specifications. The percent relative standard deviation of the six preparations for
polyvinylpyrrolidone was found to be 0.3%. In order to further validate the results, the
experiment was conducted again on a different day using a different instrument, column
and analyst. In addition the work was repeated at a different work site, using different
instruments and different columns.
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Figure 12: Overlay stress studies chromatograms for (a) ophthalmic solution without polyvinylpyrrolidone
(b) ophthalmic solution (C) polyvinylpyrrolidone standard
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Linearity of Polyvinylpyrrolidone
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Figure 13: Linearity graph of Polyvinylpyrrolidone (PVP). PVP found to has a linear response over a range
of 50%-150% of theoretical concentration 0.1 mg/mL
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Target
Concentration
Level

Concentration
(mglmL)

Response
(Peak Area)

50%

0.05225

320089.74

80%

0.083600

512627.13

100%

0.104500

640589.55

130%

0.135850

838004.55

150%

0.156760

969587.72

Slope

62616701.63

Y Intercept (%)

·6470.92

Correlation

0.99995

Table 5: Linearity parameters of polyvinylpyrrolidone (PVP). PVP found to has a linear response over a
range of 50%-150% of theoretical concentration 0.1 mglmL
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Replicate #

Peak Response (Area)
601997.31
601504.28
601485.97
600671.02
601882.20
601477.17
601502.99
0.1

1
2
3

4
5
6
Mean
%RSD

I

(a)

Replicate
1

% Label Claim of Povidone (%LC)
Reproducibility
Intermediate Precision
Analyst llLab 1
Analyst 2ILab 1
Lab 1
Lab 2
102.4
102.0
102.0
102.0

2

102.3

101.9

102.3

102.9

3

102.4

102.1

102.4

102.9

4

102.8

103.3

102.8

103.1

5

101.9

101.4

101.9

102.7

6

102.6

102.7

102.6

102.8

102.3

102.2

102.3

102.8

0.3

0.7

0.3

0.2

. Mean
%RSD
Mean Agreement

0.5

0.1
(b)

Table 6: Experimental results for (a) system precision and (b) intermediate method precision and
reproducibility results
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The experimental mean agreement for povidone between the two days and sites was
found to be 0.1 and 0.5 respectively and is within the acceptance criteria. Results are
displayed in Table 6b.
The accuracy of the method was established by assaymg three different
concentration levels 70%, 100%, and 130% ofthe theoretical concentration.
Six preparations of ophthalmic formulation without polyvinylpyrrolidone, at each level,
were spiked with standard of polyvinylpyrrolidone and were injected into the HPLC
system. Results are reported in Table 7a with polyvinylpyrrolidone mean recovery values
varied from 100.0 to 100.8% of the prepared standard concentration.

No bias was

observed for polyvinylpyrrolidone, since the results for the mean recovery from all three
accuracy levels were not significantly lower or higher (±l.S%) than the theoretical value.
The range in which the method is shown to be linear and accurate for povidone is
between 70-130% of theoretical concentration.
The method was unaffected by small, deliberate variations in chromatographic
parameters and mobile phase preparation.

The parameters tested were detector

wavelength (+1- 4 nm), mobile phase flow rate (+1- 0.1 mL/min) and temperature (+1
5°C).

Retention time and the peak shape were not affected by these parameters. The

variation in results that was observed between the normal method conditions and the
changed parameters were from 0.1 to 1.6% for povidone. Table 7b shows the results that
were obtained by the'robustness studies of polyvinylpyrrolidone.
Different lots of polyvinylpyrrolidone raw materials were used to evaluate the
impact on the assay values using polyvinylpyrrolidone other than the one used in the
formulation batch. In addition, the USP reference standard of polyvinylpyrrolidone was
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Pre #

1
2
3
4
5
6
Mean
%RSD
(a)

% LC of povidone
102.8
103.6
103.8
102.7

Percent ditTerence

Control
Flow 0.9ml/rnin
Flow l.1ml/min
Column temperature 45· C
Column temperature 55· C

103.1

-0.3

Mobile Phase - 10%
Mobile Phase + 10%
Wavelength at 216nm
Wavelength at 224nm

103.5
104.4
102.9
103.6

-0.7
-1.6
-0.7
-0.9

Parameters under study

N/A
-0.8
-1.0
0.1

(b)

Table 7: Experimental results for (a) Accuracy results (Ophthalmic solution without polyvinylpyrrolidone
spiked with standard solution of polyvinylpyrolidone at three levels, 70, 100, 130% of theoretical) and (b)
robustness studies of polyvinylpyrolidone
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evaluated to quantitate polyvinylpyrrolidone in ophthalmic solutions. One sample
preparation was run with five different raw material polyvinylpyrrolidone standards and
one USP reference standard as per method. Table 8a summarizes the results of this test.
An attempt to explain the variability on the results the water content of each standard of
polyvinylpyrrolidone was determined by Karl Fischer as per USP 30 <921> method I.
It should be noted that standard 6 is the USP standard and water content was not
performed for this standard because it was dried prior to its use. Table 8b summarizes the
water content results of polyvinylpyrrolidone. The water content results explain the
variability on the assay sample results that were observed when different standards were
used. If results corrected for water content then they are a lot closer to each other and the
differences between them are within experimental error of the analytical method. Table
8c shows the results taking into account the water content.
The stability of the standard and sample solutions for povidone was also evaluated.
No significant change in PVP response was observed over a period of 192 hrs. Solutions
stored at refrigerator and ambient temperature. Samples tested at the same time and
results between the two conditions were comparable. Table 9 shows the solution stability
of both standard and sample at ambient temperature.
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Standard 1

Standard 2

Standard 3

Standard 4

Standard 5

Standard 6

Povidone

Povidone

Povidone

Povidone

Povidone

Povidone

% Label Claim

Assay

102.7

106.8

N/A

4.1

i

106.4

105.1

107.0

101.3

3.7

2.4

4.3

1.4

Absolute
difference
from
Standard 1 I
(a)

I

I

Standard 1

Standard 2

Standard 3

Standard 4

Standard 5

Standard 6

Povidone

Povidone

Povidone

Povidone

Povidone

Povidone

% water content
Water
content

3.84

6.42

6.81

4.93

7.11

N/A*

N/A

2.58

2.97

1.09

3.27

N/A

Absolute
difference
from
Standard 1

I

i

..

* Waler content of USP standard not determmed SInce It IS dned pnor to use
(b)

I

Standard 1

Standard 2

Standard 3

Standard 4

Povidone

Povidone

Povidone

Povidone

I

Standard 5 Standard 6
Povidone . Povidone
i

% Label Claim

Assay

98.7

99.9

99.2

N/A

1.2

0.5

99.9

99.4

101.3

1.2

0.7

2.6

Absolute
difference
from

!

Standard 1

I
(c)

Table 8: Evaluation of polyvinylpyrrolidone assay using different raw material (a) assay results of
ophthalmic formulation using different raw materials of polyvinylpyrrolidone as a standard. (b) water
content of polyvinylpyrrolidone standards, (c) assay results of ophthalmic formulation taking into account
the water content of polyvinylpyrrolidone
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Standard
Time Point

Sample

% Label Claim of polyvinylpyrrolidone (% LC)

Initial

99.5

102.0

24 Hours

99.9

10204

4 Days

100.8

102.8

8 days

lOlA

104.3

Table 9 Solution stability studies of polyvinylpyrrolidone at ambient temperature
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I

3.4 Conclusion

A new method for the determination of total polyvinylpyrrolidone in ophthalmic
solutions was developed using SEC-UV with quantitation of the analyte peak eluting
before

the

void

volume

disturbance.

This

unique

combination

separated

polyvinylpyrrolidone from other formulation components and allowed a simple isocratic
method. Validation for this method was performed according to ICH guidelines and met
all acceptance criteria. The method is precise (+/- 0.1 %), accurate (+/- 1%), and linear at
concentration ranges of 0.07 mg/mL to 0.13 mg/mL, typical of prepared ophthalmic
solution samples for polyvinylpyrrolidone.

Several unusual chromatographic situations

were used together successfully in this work: SEC with UV detection and quantitation of
a chromatographic peak eluting before the void volume. This method provides a model
for the analysis of a polymeric component in the presence of monomeric components in a
number of different types of formulations.
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Chapter 4: Demulcents (PEG400 and Glycerin)

4.1 Introduction

An array of over the counter (OTC) ophthalmic solutions is available for the
self treatment of minor ophthalmic disorders. Common treatments for minor eye
episodes include the use of OTC ophthalmic lubricants, including artificial tears
products which contain polyethylene glycol 400, and glycerin. The use of lubricants
offers many advantages. From a chemical composition perspective, they are used to
control the viscosity of the solutions. They also offer a medicinal benefit: to relieve
pain in inflamed or irritated mucous membranes.
Glycerin was synthesized by the Swedish scientist K. W. Scheele in 1779, as a
result of heating a mixture of olive oil with lead monoxide. He published this method in
1783 after noticing other metals and glycerides produced the same chemical reaction
which yields glycerin and soap. However, it was not until 1811 when the French
investigator M. E. Chevreul discovered the immeasurable properties of glycerin. He
named the compound glycerin after the Greek word glykys, meaning sweet. Twelve years
later he patented a new way to produce fatty acids from fats when treated with alkali in

II

which glycerin was released. The first empirical formula of glycerin (C 3H s03) was

,

announced in 1835 by French investigator Pelouze. About fifty years later, in 1883,

i

Berthelot and Lucea established the accepted formula of glycerin C3Hs(OHh [75-76].

~

i

:!:1
1
,
l

.1

II

i

The unique chemical and physical properties of glycerin including that it is not
toxic to the digestive system and not a skin irritant, make glycerin applicable in a variety
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of applications within the chemical, pharmaceutical, consumer, and food industries [77].
In ophthalmic solutions, glycerin is generally present at approximately 0.2%
concentration in an aqueous matrix containing other formulation components and active
therapeutic ingredients. Glycerin is also used as a lubricant to relieve symptoms of dry
eyes such as burning, and itching, which are caused by exposure to wind, sun, heating, air
conditioning, and extended computer use.
Chemically, glycerin is a very stable alcohol. It has three hydroxyl groups which
can react with other chemical groups, thereby permitting the synthesis of many different
derivatives with specific applications [78]. Physically, glycerin is a clear and viscous
liquid miscible with water and alcohol. At low temperature glycerin does not crystallize
which makes it a favorable candidate for cooling systems such as antifreeze. However,
the most important property of glycerin is its ability to absorb and hold moisture from the
air. This unique property, in conjunction with a glycerin-water solution makes glycerin a
suitable agent for plasticizers which give products the desired shelf life, flexibility and
softness. Glycerin is found in nature in the form of triglycerides and occurs naturally in
beers, wines, breads and other products of grains and sugars.
As was mentioned above, glycerin has three hydroxyl groups. Two of these
groups are primary and the other secondary [79]. Figure 14a shows the structure of
glycerin. The two primary hydroxyl groups are more reactive than the secondary but in
some reactions the secondary hydroxyl group can react before all the primary groups are
exhausted. Industrially, glycerin is produced during saponification from fats and oils after
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HO

OH
OH

Structure name: propane-l,2,3-triol
Molecular formula: C 3Hg03
Formula weight: 92.09
(a)

OH

Structure name: Polyethylene Glycol
Molecular formula: CnH4n+20n+l> n=8.2 to 9.1
Formula weight: 380-420
(b)

Figure 14: Structures of a) Glycerin and b) PEG400
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Hydrolysis. It is recovered in a crude state and purified by ion exchange or distillation
[75].
Glycerin is analyzed with different techniques that are labor intensive and in
many instances not stability indicating. A more specific assay of glycerin in the United
States Pharmacopeia is accomplished by periodate oxidation titration. Glycerin is
oxidized by potassium periodate to form fornUc acid, then the solution is titrated with
standard potassium arsenite and the liberated iodine is indicated by the starch-iodine
reaction [80].
Glycerin and its derivatives have been chromatographically analyzed by a variety
of techniques including thin layer chromatography (TLC), gas chromatography (GC).
capillary electrophoresis (CE). ion chromatography and HPLC utilizing different
detectors. ultra violet (UV). charged aerosol detector (CAD) [81-86]. A large number of
chromatographic methods for the determination of glycerin have been also reported in
biodiesel research literature [87-102]. Biodiesel is a renewable fuel from natural oils like
soybean oil. rapeseed oil or animal fats and produced by transesterification reaction of
these oils/fats with alcohol to yield smaller molecules (FAMES). Their properties are
close to diesel fuel. However. during this process glycerin also is generated as by-product
of the reaction and needs to be removed because it can be harmful to the engine. There is
a maximum amount of free and total glycerin that permitted in the fuel and is limited to
0.02% and 0.24% respectively (0.25% for European) [103]. Figure 15 shows such a
reaction.
Glycerin is a metabolic precursor for the synthesis of triglycerides and membrane
phospholipids. The serum content of glycerin is correlated as a marker of cardiovascular
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H2C-OCOR1

I

HC-OCOR2

I

+

3CH3OH

...

Basic Catalyst

H2C-OCOR3

Vegetable Oil

..

R1COOCH 3
R2COOCH 3
R3COOCH 3

Biodiesel
(FAME)

Methanol

H2C-OH

+

I

HC-OH

I

H2C-OH

Glycerin

Figure 15: Transesterification reaction of triglycerides to fatty acid methyl esters [92]

63

disease [104] and the plasma, tissue content of glycerin is considered and index of
cardiac triglyceride metabolism [105]. A significant number of publications exist in this
area for the analysis of polyhydroxyl compounds using thin layer chromatography, [106
107] enzyme linked assays, [108-109] pulsed amperometric detection, [110] mass spectra
analysis [111-112] and UV detection [113-118].
Polyethylene glycol is a polyether compound with many applications to consumer
and pharmaceutical products. Manufactured by the polymerization of ethylene oxide with
either water, mono ethylene glycol or diethylene glycol under alkaline catalysis. Ethylene
glycol and ethylene glycol oligomers are preferred over water because the products of
such reactions are polymers with smaller range of molecular weight (low polydispersity)
[119-120].
After the desired molecular weight was reached, the reaction is terminated by
adding an acid to neutralize the catalyst. The molar mass distribution of polyethylene
. glycol defines the different grades assigned for this chemical substance. The various
grades of polyethylene glycols are not uniform compounds, but rather mixtures of similar
polymer members. For that reason, controlling the polymerization is a very important
step in the production of polyethylene glycol. Molar mass distribution is assigned by gel
permeation chromatography (GPC) in which analysis is based on the different migration
rates of the polymer mixture in microporous gel. In general, each polyethylene glycol
follows by a number which is the average molecular weight of the polymer.
Polyethylene glycol with the general formula H(OCH2CH3)nOH can be in both
liquid or solid form based on the size of the molecular weight [121]. Structurally the
shorter chains, (with a degree of polymerization less than 10) form a zigzag structure,
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while the longer chains are in the crystalline state, form a twisting / spiral like structure
where the oxygen atoms form ether bridges at regular intervals. Figure 14b shows the
structure of PEG400.
Chemically the hydroxyl end groups of polyethylene glycol have a significant role
in the physical and chemical properties of these molecules and for that reason molecules
of molecular weights 200-35000, are referenced as polyethylene glycols and not
polyethylene oxides.
Physically these molecules are clear, viscous liquids or white solids which
dissolve in a variety of solvents including water to form transparent solutions. They are
soluble in aromatic hydrocarbons and slightly soluble in aliphatic hydrocarbons.
Polyethylene glycols are very stable molecules which do not hydrolyze or otherwise
deteriorate upon storage and do not support mold growth. They are compounds of low
toxicity and for that reason are widely applicable in many different industries [122]. In
ophthalmic solutions, PEG400 is used as a moisturizer, and is generally present at
approximately 1% concentration in· an aqueous matrix containing other excipients and
active pharmaceutical components. PEG400 is used to adjust the viscosity of the solution
and to enhance the solubility of other poorly soluble components in the formulation. The
formulation viscosity is a critical parameter in ophthalmic solutions because it enables the
formulation to remain in the eye longer and gives more time for the drug to exert its
therapeutic activity or undergo absorption.
Smaller range molecular mass polyethylene glycols are used extensively in the
pharmaceutical industry and in clinical research [123]. Therefore there are many
requirements for accurate quality control and product characterization methods. It should
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also be noted that chromatography is the preferred method for analyzing such compounds
[124-132]. Other methods such as colorimetry, [133] turbidimetry, [134] Fourier
Transform IR (FTIR) [135] can provide only bulk information about polyethylene glycols
and are subject to interference. Paper chromatography methods have been used for the
determination of polyethylene glycols but the method is limited in sensitivity and
repeatability [136]. Capillary gel electrophoresis has also been reported in the literature
for the separation of the polyethylene glycols but this method, too, has its limitations to
column fragility and cost [137]. Derivatization techniques are widely used for the
separation of polyethylene glycols due to the popularity of the conventional UV detector.
These techniques also allow the use of fluorescent detectors, minimizing interference and
increase the detection limits [138-140]. UV detection without using derivatisation was
also reported in the literature but the use of sodium azide in the mobile phase was needed
to minimize solvent absorbances of mobile phase components. However, the baseline
drift still posed a problem [141]. An evaporative light scattering detector was
successfully implemented in the determination of polyethylene glycols without·
derivatization [142]. More expensive mass spectrometer detectors are not widely used
and are not available to every laboratory have been used for the analysis of polyethylene
glycols [143-145].
Based on extensive investigation of the literature no method appeared to report
the simultaneous determination of PEG400 and glycerin in ophthalmic solutions. One
paper was found for the determination of PEG400 in ophthalmic solution but it was using
two different columns in series to separate PEG400 from other components in the
formulation. It should be noted, that the method applicability in this work was limited to
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a specific type of ophthalmic formulation and the length of each column used was 300
mm which made the instrument arrangements a bit more complicated. In addition the
mobile phase used in this publication was methanol and the buffer system consisted of by
. three different components, making the pre-run system preparation time consuming [146].
In this work a new method is described for the analysis of PEG400 and glycerin

in ophthalmic solutions. The analytical procedure is a simple, direct HPLC method that is
based on Size Exclusion Chromatography (SEC). The sample is diluted with water and
injected into a HPLC instrument equipped with TOSOH Bioscience TSKgel GIOOOPW,
7.5 mm ID x 30 cm, 10 Jlm column at 50°C. Quantitation is achieved by comparison of
peak heights of PEG400 and glycerin in the sample to that of a known concentration
reference standard. PEG400. and glycerin are separated from other components in the
formula and detected by a Waters Refractive Index (RI) detector.

4.2 Experimental

4.2.1 Reagents and Chemicals

The raw material for PEG400 was purchased from P&G Chemical (Cincinnati,
OH, USA) and the raw material for glycerin was purchased from Clariant Produkte
(Gendorf, Germany). HPLC water grade was purchased by J.T. Baker (Phillipsburg, NJ,
USA).
Laboratory formulations of typical opthalmic solutions were prepared in water at
0.57 mg/mL and 0.13 mg/mL concentration of PEG400 and glycerin respectively. They
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were diluted by adding 5 mL of formulation to a 100 mL volumetric flask and diluting to
the mark with water prior to HPLC analysis. The standard working concentrations of the
standard solutions were 0.57 mg/mL and 0.13 mg/mL for PEG400 and glycerin
respectively. They were prepared by weighing 130 mg of glycerin into 50 mL volumetric
flask and diluted to the mark with water (glycerin stock solution). Working standard
concentrations were prepared by weighing 114mg of PEG400 into 200 mL volumetric
flask and pipette 10 mL of glycerin stock mix well and diluted to the mark with water.
The working standard concentrations were 0.57 mg/mL and 0.13 mg/mL for PEG400 and
glycerin respectively.

4.2.2 Instrumental Conditions

An Alliance HPLC system equipped with a 2695 separation module with a
differential refractive index detector model 4210 was used for all experiments. Data
collection and processing was performed using an Empower chromatographic data
acquisition system.

(Waters Corporation, Milford, Massachusetts, USA)

The

chromatographic column was a TSKgel G2000PW, 7.5 mm ID x 30 cm, 12 J.lm column
(TOSOH Bioscience, Tokyo, Japan). The flow was kept at 1.0 mLimin during the length
of the run and the column temperature was 50°C. The refractive index detector settings
were: sensitivity 64, filter (TC) 3, cell temperature 35°C. The injection volume was 10
J.lL and the mobile phase was water vacuum degassed for fifteen minutes prior to use.
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4.2.3 Testing Parameters

Testing of the chromatographic method was performed in accordance with
International Conference on Harmonisation (ICH) guidelines and typical operating
procedures for pharmaceutical analysis. The test parameters are presented in the same
order as they were investigated during the method validation. Specificity was determined
by exposing ophthalmic solution samples, placebos, and standards of PEG400, glycerin
to stress conditions of acid, base, hydrogen peroxide, light, and heat. Subsequently, the
solutions were analyzed according to the method presented in this paper to ensure no
extraneous peak co eluted with the actives. A refractive index detector was used during
validation to ensure that no interfering compounds co-eluted with PEG400 and glycerin.
Accuracy was measured by spiking ophthalmic solutions without PEG400 and glycerin
with PEG400 and glycerin at three working levels of 70%, 100%, and 130% of the
standard concentration. Actual concentrations tested for PEG400 I glycerin are: 0.399
mg/mL I 0.089 mg/mL, 0.57 mg/mL I 0.13 mg/mL, 0.74 mg/mL / 0.169 mg/mL. Six

preparations were performed at each level and assayed as per method conditions. The
average result from each individual level was compared to its respective theoretical
concentration value to check for any potential bias.
To ensure that the method was linear in the working concentration range, five
concentration level solutions of PEG400 and glycerin, corresponding to 0.287-0.862
mg/mL for PEG400 and 0.064-0.192 mglmL for glycerin (about 50-150% of the expected

analyte concentration) were prepared and injected. In addition, the ability of the system to
retain and carryover the analyte into subsequent injections were evaluated by injecting a
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blank solution (diluent only) in duplicate immediately after the 150% linearity level. To
ensure performance of the system before and during the analysis, system performance
parameters, as defined in USPINF, were established as a direct result of ruggedness and
robustness experiments [147].
System precision was determined using six replicate measurements of a 100%
theoretical concentration standard solution (0.57 mg/mL and 0.13 mg/mL for PEG400
and glycerin concentration respectively) containing PEG400 and glycerin, with an
acceptance criterion of the RSD being less than 2.0%. Repeatability was determined by
six identical sample preparations of the same lot. To determine agreement among test
results obtained from mUltiple samplings of the same lot of samples on different days
using different instruments, columns and analysts, six identical samples from the same lot
were prepared and analyzed.
Robustness was determined by examining small variations in: flow rate (± 0.1
mUmin) , column temperature (± 5°C). These parameters were changed one at a time.
System suitability and sample runs were both conducted with unchanged method
parameters and modified parameters. In addition a quantitative comparison study was
performed between the raw material that was used to prepare the batch and other raw
materials of PEG400 and glycerin including a USP reference standard. Three sample
preparations were run and quantitated with four different standards as per the method.
Further, to assess sample stability, standard and sample solutions were stored at room
temperature and tested at initial, 24 hrs, 48 hrs, 72 hrs, 168 hrs and for some formulations
up to 216 hrs. The solutions were tested against a freshly prepared standard at each time
point.
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4.3 Results and Discussion

4.3.1 Developmental Work

The physical and chemical properties of PEG400 and glycerin have been well
established. The UV detector is possibly the most versatile and useful detector in high
performance liquid chromatography, however it is not as widely used in SEC since many
polymers do not absorb electromagnetic radiation in the UV range [35]. Utilization ofUV
detection is possible if derivatization is being used. However, it would be difficult to
derivitize both analytes at the same time and analyze them simultaneously, not to mention
the added complexity of the sample preparation. For these reasons and the fact that both
compounds do not absorb electromagnetic radiation in the UV range, differential
refractive index detection was selected for this work. Refractive Index is a universal
detector and is widely used in size exclusion chromatography (SEC) for compounds
without significant chromophore [70]. Detection is achieved by monitoring changes in
the refractive index of the mobile phase in the presence of PEG400 and glycerin
molecules. Thus the combination of SEC with refractive index detection is especially
suited to this application.
The main goal during method development was to have an isocratic method that
separates PEG400 and glycerin from other compounds in the formulation or degradation
products.

In this study that was not necessary since the molecular weight range of

PEG400 and glycerin were well defined, approximately 400 g/mol (range 380-420 g/mol)
for PEG400 and 92.09 gimol for glycerin and that information was furnished by the
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vendor.

Initially, several size exclusion columns from different manufacturers were

screened and TSK-gel G2000PW. 7.5 mm ID x 30 cm x 12 ~m column was selected
based on symmetrical peak shape of PEG400 and glycerin. TSK-gel columns in general
consist of hydrophilic polymethacrylate spherical beads with sizes ranging from 12 ~m to
17

~m.

These types of columns are suitable for the analysis of water soluble polymers

and more specific the G2000PW is suitable for small (2000 Da and less) molecular
weight polymers. As seen in Figure 16, in our method the TSK-gel G2000PW column is
used in the expected context with smaller molecular weight analytes (glycerin) eluted
later than analytes with higher molecular weight (PEG400). Other compounds present in
the formulation, with molecular weights less than 2000, elute in the separation range of
the column and if they are are smaller than glycerin will be eluted substantially later. If
they are larger than PEG400 will be eluted earlier than the PEG400. In many of the
sample chromatograms that were obtained, an additional peak was observed prior to
PEG400 peak which we believe to be hydroxypropyl methylcellulose (HPMC): another
polymer (higher in molecular weight than PEG400) used in ophthalmic solutions. Figure
16 shows a chromatogram of this run with all three peaks (HPMC, PEG400, glycerin)
separated.
In general, polymers outside the upper limit of the exclusion volume range of the
column will elute before the void volume. While uncommon, quantifying a peak eluting
before the void volume has been recently reported in a similar context for the group assay
of polyvinylsulfonic acid impurities in 2-(N-morpholino)-ethanesulfonic acid and
polyvinylpyrrolidone [35, 71].
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Figure 16: Sample chromatogram with hydroxypropyl methy1cellulose (HPMC), PEG400 and
glycerin
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Figure 17 clearly shows a very symmetrical peak for PEG400 and glycerin,
demonstrating a satisfactory tailing factor for system performance. The validation data
presented below demonstrate adequate precision.
In an ideal SEC method separation is based on molecular size of the analyte
relative to the pore size of the packing material without any interactions between the
analyte and the packing materiaL However, a small number of weakly charged groups at
the surface of the packing material can cause changes in elution order or peak distortion.
Mobile phase selection is important to avoid enthalpic interactions between the analyte
and the packing material. There are a variety of solvents compatible with TSK-GEL
columns, so the selection process depends on the chemical structure, ionic nature and
solubility of the analytes [72]. In this study, water was used as the ideal mobile phase
because both PEG400 and glycerin are soluble in water. A good peak shape was observed,
with the expected elution order, which is a clear indication that there are no interactions
between the packing material and the analytes. To avoid microbial growth in the column
which can cause erroneous peaks and peak distortion in future analyses the column rinsed
with 0.5% sodium azide prior to storage [124].
Temperature

adjustment

can

reduce

the

analysis

time

and

improve

chromatographic performance. More specifically, as the· temperature increases, the
viscosity of the mobile phase decreases and the diffusivity of the analyte increases. Fast
size exclusion chromatography has been discussed in the literature and temperature is one
of the primary parameters adjusted to achieve faster analysis times [73-74]. Optimum
chromatographic performance was obtained in this method with column temperature at
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Figure 17: Chromatogram of PEG400 and glycerin standard (a): Full scale chromatogram (b): Expanded
chromatogram
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4.3.2 Experimental Work

Figure 18 shows the analysis of PEG400 and glycerin in several different
formulations that contain both PEG400 and glycerin (top), only glycerin (middle) and
only PEG400 (bottom). PEG400 and glycerin do not appear in the placebo
chromatograms because it is simply a formulation prepared without the analytes used to
demonstrate that other compounds that commonly appear in ophthalmic formulations will
not interfere with the method. Figure 19 shows overlay standard chromatograms with
ophthalmic solutions that doesn't contain PEG400 and glycerin, glycerin (top) and
PEG400 (bottom). These chromatograms clearly demonstrate that SEC can be used for
the separation of PEG400 and glycerin from other formulation components.
Chromatographic performance of the system was evaluated for each run by measuring the
precision of six injections of PEG400 I glycerin working standard, tailing factor,
resolution between analytes or any excipient that elutes close to method analytes.
The specificity of the method was tested by stressing standards of PEG400 I
glycerin and ophthalmic solutions with and without PEG400 I glycerin. No interference
was observed for the PEG400 and glycerin peaks from the forced degradation samples
and standards. During these studies equivalent amounts as per method of ophthalmic
solution samples, ophthalmic solution without PEG400, glycerin, and PEG400, glycerin
standard were stressed for the following conditions: (1) heat at 75°C for 1 hr; (2) 5 mL of
1 N hydrochloric acid at 75°C for 1 hr; (3) 5 rnL of 1 N sodium hydroxide at 75°C for 1
hr; (4) 5 rnL of 30% hydrogen peroxide at 75°C for 1 hr; and (5) light exposure for 24 hrs
as per ICH option 1.
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Figure 18: Different sample chromatograms (a) contain both PEG400 and Glycerin. (b) only
glycerin, (C) only PEG400
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Samples during this option were exposed to light providing an overall illumination of not
less than 1.2 million lux hours and an integrated near ultraviolet energy of not less than
200 watt hours/square meter. Subsequently the solutions were cooled to room
temperature, neutralized (if needed) and analyzed according to the test procedure. To
ensure that the method is stability indicating and no extraneous peaks co-eluted with the
peaks of interest, the stress samples of ophthalmic solutions and standards were run for
60 minutes. No interference was observed during stressing of these samples. A peak that
was observed at an approximate retention time of 12 minutes during stressing (with
hydrogen peroxide in all of the samples) is attributed to peroxide solution and is not
related to degradation of PEG400 and glycerin. Figure 20 shows overlay chromatograms
of ophthalmic solutions without glycerin (a) without PEG400 (b) and complete
ophthalmic solution sample (c) at different stress conditions.
Linearity of the method was established by injecting five standard concentrations
of PEG400, glycerin and preparing a calibration curve by plotting PEG400, glycerin
response versus concentration. The solutions covered a concentration range of 0.287 
0.8622 mglmL for PEG400 and 0.0642 - 0.1925 mglmL for glycerin. The linearity curve
for PEG400 and glycerin are presented in Figures 21 and 22. The solutions covered a
range of 50%-150 % of theoretical concentration 0.128 mglmL and 0.5748 mg/mL of
glycerin and PEG400 respectively. The method was linear in this range with R2 values of
0.9999. Concentration of linearity solutions, responses and linearity parameters such as
slope, y-intercept, and coefficient of determination are listed on Tables 10 and 11. No
carryover was observed into blank injections immediately after the highest level linearity
standard, ensuring independence of the samples.
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Figure 20: Overlay chromatograms of ophthalmic solutions without glycerin (a) without PEG400 (b) and
complete ophthalmic solution sample (c) at different stress conditions
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Target
Concentration
Level
50%
80%
100%
130%
150%

Concentration
(mglmL)

Response
(Peak Height)

0.2874

6707.58

0.4311

10017.79

0.5748

13326.56

0.7185

16683.16

0.8622

20012.49

Slope

23156.01

Y Intercept (%)

39.44

Correlation

0.999993

Table 10: PEG400 linearity parameters
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Figure 22: Linearity graph of glycerin
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Target
Concentration
Level
50%
80%
100%
130%
150%

Concentration
(mglmL)

Response
(Peak Height)

0.064150

3442.01

0.096225

5173.94

0.128300

6878.86

0.160375

8637.95

0.192450

10384.94
54091.567

Slope
Y Intercept (% )

-36.408

Correlation

0.999972

Table 11: Glycerin linearity parameters
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System precision was established by six replicate measurements of a 100%
theoretical standard solution of PEG400 and glycerin. The %RSD for PEG400 and
glycerin was found to be 0.1% and 0.4% respectively. Table 12a shows the system
precision results, mean and standard deviation.
Repeatability was evaluated by six identical sample preparations of a
homogeneous batch and the results were found to be within the specifications. The
percent relative standard deviation of the six preparations for PEG400 and glycerin was
found to be 0.5% and 0.2% respectively. In order to further validate the results, the
experiment was conducted again on a different day using a different instrument, column
and analyst. In addition the work was repeated at a different work site, using different
instruments and different columns.

The experimental mean agreement for PEG400

between the two days and sites was found to be 1.6% and 0.4% respectively. This is
within the acceptance criteria. Results are displayed in Table 12b. The experimental
mean agreement for glycerin between the two days and sites was found to be 1.2% and
0.2% respectively; also within the acceptance criteria. Results are displayed in Table 12c.
The accuracy of the method was established by assaying three different
concentration levels 70%, 100%, and 130% of the theoretical concentration. Six
preparations of ophthalmic solutions without PEG400 and glycerin, were spiked at each
level with standard of PEG400 and glycerin and were injected into the HPLC system.
Results are reported in Table 13a with PEG400 mean recovery values varying from
99.7% to 100.0 % of the prepared standard concentration. No bias was observed for
PEG400, because the results for the mean recovery
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I

Replicate #

1
2
3
4
5
6
Mean
%RSD

i
I
I
I

:
I

I

Peak Response (PEG400)
Peak

14567.82
14520.11
14510.00
14528.96
14540.22
14517.93
14530.84
0.1

Peak Response (Glvcerin)
Hei~ht

5840.56
5872.62
5869.59
5892.72
5910.14
5890.99
5879.44
0.4

I

(a)
I
I

i

Replicate

1
2
3
4
5
6
Mean
%RSD
i
Mean Agreement

% Label Claim of PEG400 (% LC)
Intermediate Precision
Reproducibility
Analyst 1ILab 1
Lab 1
Analyst 2ILab 1
Lab 2
100.2
100.9
101.0
• 100.9
101.7
99.8
101.7
101.7
102.0
100.6
102.0
101.5
102.6
99.9
102.6
101.4
101.5
101.5
99.9
101.5
101.4
101.4
100.1
101.0
101.7
.101.7
100.1
101.3
0.5
0.3
0.5
0.3
1.6%
0.4%

i
i

I

I
I

I
I
I

I
I

(b)

I
Replicate

I
2
3
4
5
6
Mean
%RSD
Mean Agreement

% Label ClaiQ'l of Glycerin (%LC)
Reproducibility
Intermediate Precision
Lab 2
Lab 1
Analyst 2ILab 1
Anal st llLab 1
99.2
99.2
101.0
199.2
99.7
99.9
100.3
99.9
100.0
99.3
101.7
I 99.3
99.5
99.7
99.7
101.0
99.3
99.6
100.7
• 99.6
98.6
99.4
99.6
99.4
99.4
99.5
100.7
. 99.5
0.5
0.2
0.7
0.2
0.2%
1.2%
(c)

Table 12: Experimental resu s (a) system precision results for PEG400 and glycerin, (b) Intermediate
method precision and reprod ~cibility results for PEG400, (c) Intermediate method precision and
reproducibility results for gh cerin
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I

i

I

I

Prep #

1

2
3
4

5
6
Mean
%RSD

PEG400
Mean Recovery Value %LC
70% Level
100% Level 130% Level·

99.9
99.6
100.0
100.0
99.0
99.6
99.7
0.4

99.7
100.0
100.1
99.9
100.3
100.0
100.0
0.2

99.8
99.7
100.4
98.7
100.0
100.0
99.8
0.6

l
I

(a)

Prep #

1

2
3
4
5
6
Mean
%RSD

Glycerin
Mean Recovery Value %LC
I
70% Level
100% Level 130% Level
I
99.6
99.6
99.2

100.2
100.3
99.5
100.0
99.0
99.8
0.5

99.9
100.0
100.2
100.0
99.9
99.9
0.4

99.7
100.0
99.7
100.1
100.3
99.9
0.3

(b)

Table 13: Experimental accuracy results of (a) ophthalmic solution without PEG400 spiked with PEG400
standard at three levels, 70, 100, 130% of theoretical (b) ophthalmic solution without glycerin spiked with
glycerin standard at three levels, 70, 100, 130% of theoretical.
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from all three accuracy levels were not significantly lower or higher (±l.S%) than the
theoretical value. Results are reported in Table 13b with glycerin mean recovery values
varied from 99.8% to 99.9% of the prepared standard concentration.

No bias was

observed for glycerin, because the results for the mean recovery from all three accuracy
levels were not significantly lower or higher (±1.5%) than the theoretical value. The
range in which the method is shown to be linear and accurate for PEG400 and glycerin is
between 70-130% of theoretical concentration.
The method was unaffected by small, deliberate variations in chromatographic
parameters and mobile phase preparation. The parameters tested were mobile phase flow
rate (+1- 0.1 mUmin) and temperature (+1- 4°C). The peak shape of PEG400 and glycerin
were not affected by these parameters but in general higher variability results were
observed for the PEG400 robustness study. The variation in results that was observed
between the normal method conditions and the changed parameters were from 0.2 to
2.3% for PEG400 and 0.1 to 0.3% for glycerin. Table 14a and 14b show the results that
were obtained by the robustness studies of PEG400 and glycerin respectively.
Two different lots of glycerin raw materials were used to evaluate the impact to
the assay values using glycerin other than the one used in the formulation batch. In
addition, USP reference glycerin standard and Sigma Aldrich glycerin were evaluated to
quantitate glycerin in ophthalmic solutions. Three sample preparations were run with four
different glycerin standards as per method. Table 15a summarizes the results of this study.
In attempt to explain the variability on the results the water content of each standard of
glycerin was investigated by assaying water content via Karl Fischer as per United States
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Parameters under study
Control
Flow 0.9mVrnin
Flow l.lml/min
Control
Column temperature 46° C

% LC of PEG400
98.8

Percent difference

lOLl
99.1
101.5
101.3

2.3
0.3

N/A

Column temperature 54° C

101.2

0.3

N/A

0.2

(a)

I

Parameters under study
Control
Flow 0.9mVrnin
Flow 1.1 ml/rnin
Control
Column temperature 46° C

% LC of glycerin
97.7
97.4
97.4
98.5
98.8

Percent difference

Column temperature 54°C

98.4

0.1

(b)

Table 14: Results of robustness studies for (a) PEG400 and (b) glycerin
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N/A
0.3
0.3

N/A
0.3

I

Standard 1

Standard 2

Standard 3

Standard 4

Raw Material

Raw Material

Sigma Aldricll

USP

% Label Claim of glycerin

Assay prep-I

101.6

97.0

97.2

97.6

Assay prep-2

101.8

97.5

97.2

97.5

Assay prep-3

101,5

96.8

96.4

96.9

Mean

101.7

97.1

96.9

97.4

N/A

4.6

4.8

4.3

Standard 2

Standard 3

Standard 4

Raw Material

Sigma Aldrich

USP

Absolute difference from

I

Standard 1

(a)

Standard 1
I Raw
Material

% water content
Water content
Absolute difference from
Standard 1

4.31

0.06

0.13

1.03

N/A

-4.25

-4.18

-3.28

Standard 1

Standard 2

Standard 3

Standard 4

Raw Material

Raw Material

Sigma Aldrich

USP

(b)

% Label Claim of glycerin

Assay prep-l

101.6

101.3

101.4

100.9

Assay prep-2

101.8

101.8

101.4

100.8

Assay prep-3

101,5

101.1

100.6

100.2

Mean

101.7

101.4

101.2

100.6

N/A

0.3

0.5

Absolute difference from
Standard 1

I

I

1.1

I

(c)

Table 15: Experimental results of (a) assay ophthalmic formulation using different sources of glycerin as a
standard (b) Water content of glycerin standards (c) Assay of ophthalmic formulations corrected for water
content
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Phannacopeia 30 <921> method 1. Table 15b summarizes the water content results of
glycerin. The water results explain the variability that was observed for the assay values
when different standards were used. Correcting the assay values for water content brings
the assay results within agreement to each other. Table 15c has the glycerin results
corrected for water content. Standard glycerin will be evaluated for water content prior of
using it for the analysis of ophthalmic solutions.
Two different lots of PEG400 raw materials were used to evaluate the impact on
the assay values of using different materials of PEG400. In addition, USP reference
PEG400 standard was evaluated by quantitate PEG400 in ophthalmic solutions. Three
sample preparations were run with three different PEG400 standards as per method.
Table 16a summarizes the results of this study. Even though the results were within
experimental error from each other, additional verifications were performed. For example,
water content of each standard of PEG400 was determined by Karl Fischer as per USP 30
<921> method I, to asure that there is no bias to assay results. Table 16b summarizes the
water content results of PEG400. A small amount of water was found by Karl Fischer
titration but assay results should not change much if they corrected. Water determination
for PEG400 standards prior to sample analysis was not necessary. Correction of assay
values for water content did not change the results drastically and results are within the
method variability and agreement to each other. Table 16c has the PEG400 results
corrected for water content.
The stability of the standard and sample solutions for PEG400 and glycerin was
also evaluated. No significant change in PEG400 and glycerin response was observed
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Standard 1

Standard 2

Standard 3

Raw Material

Raw Material

USP

% Label Claim of PEG 400

Assay prep-l

100.3

99.2

100.3

Assay prep-2

99.9

98.7

100.7

Assay prep-3

99.6

99.4

100.9

Mean

99.9

99.1

100.7

N/A

0.8

0.8

Absolute difference from
Standard 1

(a)

Standard 1

Standard 2

Standard 3

Raw Material

Raw Material

USP

% water content
i

Water content
Absolute difference from
Standard 1

0.82

0.09

0.44

N/A

-0.73

-0.38

(b)

Standard 1

Standard 2

Standard 3

Raw Material

Raw Material

USP

I
I

% Label Claim of glycerin

I

Assay prep-l

100.3

99.9

100.7

Assay prep-2

99.9

99.4

101.1

Assay prep-3

99.6

100.1

101.3

Mean

99.9

99.8

101.0

N/A

0.1

1.1

Absolute difference from
Standard 1

(c)

Table 16: Experimental results of (a) assay ophthalmic formulation using different sources of PEG400 as a
standard (b) Water content of PEG400 standards (c) Assay of ophthalmic formulations corrected for water
content
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over a period of 192 hours. Solutions were stored at refrigerator and ambient temperature.
Samples tested at the same time against freshly prepared standards of PEG400 and
glycerin and results between the two conditions were comparable. Reference tables 17
and 18 for the solution stability of both standard and sample respectively at ambient
temperature.

4.4 Conclusion

A new method for the simultaneous determination of total PEG400 and glycerin in
ophthalmic solutions was developed using SEC with refractive index detector. This fast,
simple isocratic method separates PEG400 and glycerin from other excipients in the
formulation. Validation for this method was performed according to ICR guidelines and
met all acceptance criteria. The method is precise (+1- 0.5%), accurate (+1- 1%), and
linear at concentration ranges of 0.064 mg/mL to 0.192 mg/mL for glycerin and 0.287
mglml to 0.862 mglmL for PEG400, typical of prepared ophthalmic solution samples for
glycerin and PEG400.

This method provides a model for the simultaneous analysis of

polymeric components such as PEG400 in the presence of other components such as
glycerin in a number of different types of formulations.
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PEG400
Time Point

I
f

Response

Glycerin

(%LC)

% Difference
from Initial

Initial

99.7

24 Hours

Response
(%LC)

% Difference
from Initial

N/A

99.9

N/A

100.2

-0.5

100.1

-0.2

48 Hours

100.5

-0.8

100.2

-0.3

72 Hours

100.7

-1.0

99.9

0.0

168 Days

101.1

-1.4

100.3

-0.4

i

(a)

PEG400
Time Point

Response
(%LC)

Glycerin

% Difference
from Initial

Response
(%LC)

% Difference
from Initial

Initial

99.7

N/A

99.9

N/A

24 Hours

100.4

-0.7

101.1

-1.2

48 Hours

100.8

-1.1

99.9

0.0

72 Hours

100.4

-0.7

100.6

-0.7

168 Days

101.4

-1.7

101.0

-1.1

(b)

Table 17: Standard solution stability studies at (a) ambient temperature (b) refrigerated
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I

PEG400

Time Point

Response

(%LC)

I

Glycerin

% Difference
from Initial

Response

(%LC)

% Difference
from Initial

Initial

101.8

N/A

104.0

N/A

24 Hours

102.7

0.9

104.7

0.7

48 Hours

102.4

0.6

104.6

0.6

72 Hours

102.3

0.5

104.2

0.2

196 Days

102.3

0.5

104.5

0.5

(a)

I

Glycerin

PEG400

I

Time Point

Response

(%LC)

% Difference
from Initial

Response

(%LC)

% Difference
from Initial

Initial

101.8

N/A

104.0

N/A

24 Hours

103.0

1.2

104.6

0.6

I

48 Hours

102.6

0.8

104.6

0.6

I

72 Hours

102.6

0.8

104.2

0.2

0.4

104.5

0.5

8 Days

102.2

(b)

Table 18: Sample solution stability studies at (a) ambient temperature (b) refrigerated
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Chapter 5: Ophthalmic Active Components

5.1 Introduction

In pharmaceutical work active components are defined by the International
Committee on Harmonization (ICH Q7A) as "any substance or mixture of substances
intended to be used in the manufacture of a drug product and that, when used in the
production of a drug, becomes an active ingredient in the drug product". Such substances
are intended to furnish pharmacological activity or other direct effect in the diagnosis,
cure, mitigation, treatment or prevention of disease or to affect the structure and function
of the body. Any ophthalmic solution is composed of two aspects. The first is the active
component which is the central ingredient or the therapeutic agent that is meant to
produce the desired effect in the body. The second is the rest of the components in the
formulation that are used to deliver the active components or play a role in solution
stability but that do not have a direct therapeutic purpose in the ophthalmic solution.
There is a variety of over the counter ophthalmic solutions that can be applied or
instilled in the eye for the treatment of symptoms such as itching, irritation, redness,
dryness, tearing, conjunctival edema, burning and discharge. There are different active
components for the symptoms above and in some instances they might be multiple
actives for the treatment of several symptoms at once.
General categories

of active components

in ophthalmic solutions are

vasoconstrictor, hypertonicity agent, emollient, astringent, and buffering agent [148]. A
vasoconstrictor is a topically pharmacologic agent that when applied to the mucous
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membranes of the eye causes constriction of conjunctival blood vessels. There are five
active components in this category that can be found in ophthalmic solutions:
oxymetazoline

hydrochloride,

naphazoline

hydrochloride,

tetrahydrozoline

hydrochloride, ephedrine hydrochloride, and phenylephrine hydrochloride. Hypertonicity
agents exert an osmotic pressure greater than that present in body tissues and fluids, so
that water is drawn out from the body tissues and fluids across semipermeable
membranes. Applied topically in the eye, they create an osmotic pressure which draws
water out of the cornea. Sodium chloride at levels of 2% to 5% is one of the most
common hypertonic agents. Emollients are usually fat or oil, which applied locally to
eyelids protect and soften tissues to prevent drying and cracking. Examples of the most
used emollients in ophthalmic formulations are lanolin, mineral oil, petrolatum, and
paraffin. An astringent is a therapeutic local agent which precipitates protein and helps to
clear mucous from the outer surface of the eye. Zinc sulfate is an example of an
astringent in ophthalmic solutions and can be found at 0.25% concentration. A buffering
agent stabilizes pH when acid or base is introduced to the eye in the form of body fluids
and tears.
Analysis of the active component, along with possible degradants and impurities
is critical to ophthalmic solutions due to the efficacy of the

~ctive

component and due to

regulatory requirements. Recently not only the purity profile but the impurity profile has
become essential for the safety of the ophthalmic formulations because small amounts of
unwanted impurities can influence the safety and efficacy. Different pharmacopoeias
such as United States Pharmacopoeia, and British Pharmacopoeia, which regulate
ophthalmic solutions, are incorporating limits for acceptable levels of known impurities

97

of active components.
In this chapter, oxymetazoline hydrochloride was chosen to be studied extensively
and additional active components which have similar structures (tetrahydrozoline
hydrochloride and naphazoline hydrochloride) were also evaluated to establish common
degradation pathways through stresS degradation studies.
One challenge in the analysis of ophthalmic solutions is the measurement of
oxymetazoline hydrochloride (OXY) and its known degradation product (N-(2
aminoethyl)-2-[4-(I,ldimethylethyl)-3-hydroxy-2,6-dimethylphenyl]-acetamide) (OXY
, DEG). Although a number of HPLC methods have been developed to determine OXY in
a variety of products, [149-153] none of these methods also determined OXY-DEG,
which appears at much lower concentration. In this work, a straightforward, isocratic
reversed-phase HPLC-UV method was sufficient to quantify both OXY and OXY -DEG
in a single analysis, although their concentrations are orders of magnitude different.
Forced degradation studies performed during method validation revealed that OXY-DEG
is likely a base hydrolysis product of OXY. In

~ddition,

other ophthalmic active

components with the same imidazoline structure were stressed and tested to verify
degradation pathway similar to the unknown of OXY. Figure 23 shows the structures of
tetrahydrozoline and naphazoline that were used during stress studies to confirm the
degradation pathway.
A simple rapid isocratic reversed-phase high performance liquid chromatography
(HPLC) method was developed for the determination of oxymetazoline hydrochloride
(OXY) and its known degradation product (N-(2-arninoethyl)-2-[4-(1,1-dimethylethyl)-3
hydroxy-2,6-dimethylphenyl]-acetamide) in ophthalmic solutions.
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H:)
N

(a)

(b)

Tetrahydrozoline
Structural name:
2-Tetralin-l-yl-4,5-dihydro-lH-imidazole
Molecular formulation: CI3Hl~2
Formula wei!!ht: 200.28

Naphazoline
Structural name: 2-(naphthalen-l
ylmethyl)-4,5-dihydro-lH-imidazole
Molecular formulation: C'4H'4N2
Formula weight: 210.274

Figure 23: Imidazoline structures (a) Tetrahydrozoline (b) Naphazoline
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Oxymetazoline hydrochloride (OXY) is a long acting vaso-constrictor that acts
directly to reduce the swelling of the nasal membranes, relieving decongestion in the
subject. In the eye, imidazole decongestants such as OXY are used to constrict
conjunctival blood vessels. More specific ophthalmic solutions that contain OXY have
been shown to improve the relief of redness in the eye due to minor eye irritations [147].
OXY is an imidazole derivative with a general formula: [CI6H24N20]· HCI, and chemical
name3-[(4,5-dihydro-1H-imidazol-2-yl)methyl]-6-( 1, 1-dimethylethyl)-2,4
dimethylphenol hydrochloride. The chemical structure of oxymetazoline hydrochloride is
presented in Figure 24.
OXY is an ingredient in a variety of over-the-counter products such as nasal
sprays and ophthalmic solutions. It was developed at E. Merck Darmstadt, Germany from
xylometazoline in 1961 [154]. OXY has sympathomimetic properties meaning it
constricts the blood vessels of the nose and sinuses through the activation of alpha
adrenergic receptors. However, the treatment should not be continued for more than
seventy two hours since excessive or improper use of topical decongestants can cause
rhinitis medicamentosa which is increased nasal congestion [155]. Recently, it has been
reported that OXY inhibits and resolves inflammatory reactions in human neutrophils
[156]; a type of white blood cell filled with neutrally-staining granules, tiny sacs of
enzymes that help the cell to kill and digest microorganisms.
Ophthalmic solutions and nasal sprays generally contain OXY at levels of 0.025%
to 0.05% respectively [147, 157]. Many high performance liquid chromatography
analytical methods have been developed to determine OXY in a variety of products [149
153, 158-159].
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Figure 24: Oxymetazoline structure
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However, none of these methods also determined the known degradation product of
Oxymetazoline: N - (2 - aminoethyl) - 2 - [4 - (1,1 - dimethylethyl) - 3 - hydroxyl - 2,6 
dimethylphenyl] - acetamide (OXY-DEG).
The European Pharmacopeia (EP) lists OXY-DEG as a known impurity of
oxymetazoline

hydrochloride

with

chemical

name

N-(2-aminoethyl)-2-[4-(l,I

dimethylethyl)-3-hydroxy-2,6-dimethylphenyl]-acetamide [160]. The chemical structure
of the impurity is shown in Figure 25. However, during the stress studies of the method
validation, it was determined that this compound is a hydrolysis product of
oxymetazoline hydrochloride which is consistent with information published in literature
[161].
The method of determination of the OXY-DEG as described in EP is different than the
one in this publication. More specific the differences are in the column dimensions, stationary
phase, column temperature, flow, wavelength, and mobile phase. The USP method is only
suitable for the assay determination of OXY and doesn't determine the OXY -DEG. In addition, in
that USP assay method the chromatographic parameters are different than the current method.
The EP assay method the determination of OXY was done with titration and not with an HPLC
[160, 162].

In this work we describe new HPLC methods for the analysis of the
oxymetazoline hydrochloride and its degradation product in ophthalmic solutions. The
new methods are stability indicating methods and were successfully validated based on
the International Conference on Harmonization guidelines [163].
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NHZ

x Hel

N

H

Figure 25: Structure of oxymetazoline degradation product (N (2 aminoethyl) - 2 - [4 - (1,1 
dimethylethyl) - 3 - hydroxyl- 2,6 - dimethylphenyl] - acetamide)
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5.2 Experimental

5.2.1 Reagents and Chemicals

Standards of oxymetazoline HCl and its degradation product were obtained from
LGC (LGC GmbH, 1m Biotechnologiepark, TGZ II, D 14943 Luckenwalde, Germany).
Samples and placebo were provided by the Johnson and Johnson product development
group (Morris Plains, NJ, USA). ACS reagent grade sodium acetate trihydrate and
reagent grade glacial acetic acid were purchased from Sigma Aldrich (Saint Louis,
Missouri, USA). HPLC grade acetonitrile was purchased from J.T. Baker (Phillipsburg,
NJ, USA). Deionized Water was used and obtained from VWR International, LLC (West
Chester, Pennsylvania, USA).

5.2.2 Equipment

An Alliance HPLC system (Waters Corporation, Milford, Massachusetts, USA)
was used for method development and validation. The Alliance LC system was equipped
with 2695 separation module, 2487 UV detector and 996 photodiode array detector. Data
collection and processing was done using Empower (Waters Corporation, Milford, MA
USA).
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5.2.6.9.2 Solution Stability: Standard and sample solutions were stored at room
temperature and tested at initial, 72 hrs and 240 hrs of standing. The solutions were tested
against a freshly prepared standard at each time point.

5.3 Results and Discussion

The analytical method for the degradation product of oxymetazoline hydrochloride is
slightly different than the assay method of OXY since the exact parameters were not
suitable to evaluate both compounds simultaneously in one method. More specifically,
the differences were in detector wavelength and injection volume. These are not unusual
since the target concentration level and UV absorbance between the OXY and
degradation product can be different. However, the determination of OXY and
degradants can be done in a single injection with the use of dual wavelength or
photodiode array UV detectors. Additional validation of the method was done at 100 ",,1
injection volume. More specific the following parameters were evaluated: system
precision, method precision, accuracy and linearity. The degradation method is also
capable of separating xylometazoline hydrochloride from OXY and OXY -DEG.
However, xylometazoline was not included into validation since it was not observed
during the stressing studies at specificity. Figure 26 shows an overlay chromatogram of
ophthalmic solution sample with mixture standard OXY -DEG and xylometazoline
hydrochloride.
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Figure 26: Overlay chromatogram of ophthalmic solution sample and degradation standard mixture
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5.3.1 Developmental Work

The physical and chemical properties of oxymetazoline hydrochloride are well
established, since that molecule has been known since its synthesis in 1961 [149]. UV
detection was selected since both oxymetazoline HCI and its degradation product have a
chromophore at UV spectrum range. Figure 27 shows UV spectra of (a) oxymetazoline
and (b) OXY-DEG.

I

i

The initial goal during the method development was to have one method for the

j

I

1

determination of oxymetazoline and its degradation product. However, it was observed
that oxymetazoline response was not linear at wavelength of 225 nm and injection
volume of 100 !AL. Optimum wavelength selection (A=225 nm) for the degradation
method was done based on the maximum absorbance of degradation product. The
wavelength (A=280 nm) of the assay method was selected based on the second maximum
absorbance of the oxymetazoline. Nevertheless, the determination of OXY and its
degradation product can be done in a single chromatographic run with the use of
photodiode array detector.
Ideally in reversed phase HPLC method development, several columns with
different stationary phases Cg, CIg, Cyano, Phenyl, should be tested based on separation
ability in the desired pH range. However, in cases that there is familiarity with the active
ingredient the use of a single column can be sufficient for method development. In this
case, the cyano stationary phase (Agilent, Zorbax SB-CN, 3.5 !Am, 150 mm x 4.6 mm)
proved capable of adequately separating all components, so testing of other columns was
not necessary.
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Figure 27; UV spectrum of (a): OXY (b): OXY -DEG
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In general, retention of less polar compounds declines with cyano columns while polar
compounds maintain retention. Many comparable studies were reported between cyano
and different stationary phases. In one such study, different cyano columns were
characterized in terms of selectivity. Comparison between cyano, C8, and C18 stationary
phases was not practical because cyano columns required weaker mobile phases with
changes in separation selectivity. Due to those differences replacement of C8, and CI8
columns with an equivalent cyano column will not be possible [166].
System performance. parameters were selected to provide confidence that the
methods are capable of determining oxymetazoline HCI and OXY -DEG in ophthalmic
solutions. Different concentration levels of oxymetazoline HCI were injected as part of
the system suitability for the two methods. Typical chromatograms for oxymetazoline
HCI standard solution are shown in Figure 28. The selected system performance
parameters were injection precision of OXY, tailing factor and signal to noise ratio of
OXY at the quantitation level. In addition, check standard conformity and bracketing
standard conformity were proved during each chromatographic run. All of these tests
produced results within the guidelines of good laboratory practices for system
performance. The system performance at 100 ""L injection volume was based on the
precision of six injections of a 100% standard at concentration 0.1 mglmL. Tailing factor
and signal to noise ratio were not evaluated as part of the system suitability. The tailing
factor that was observed during the validation at this injection volume was greater than
the previous acceptance criteria of 0.8-2.0. This is not unusual since the amount of OXY
in the column is ten times higher than the 10 ""L injection. Also, during this injection
adequate signal to noise ratio was observed which make this parameter unessential to
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Figure 28: Chromatograms of oxymetazoline for (a): Assay method (b): Degradation method
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monitor as part of the system suitability. Typical chromatogram for the oxymetazoline
Hel standard is shown in Figure 29. In addition, check standard and bracketing standard
conformity were proved during validation. Samples bracketed with two different
standards to accommodate the simultaneous determination of OXY and unknown
degradants in the sample. The standard concentrations were 0.1 mg/mL and 0.001 mglmL
for assay and degradation respectively. System suitability tests produced results within
the guidelines of our standard operating procedures.

5.3.2 Experimental Work

The specificity of the methods (assay and degradation) was tested and no
interference from inpurities or degradants was observed for the oxymetazoline
hydrochloride and its degradation product peaks from placebo and forced degradation
samples using acid, base, light, hydrogen peroxide and heating. To ensure no extraneous
peak co-eluted with the OXY or its degradation product, a UV diode array detector was
used to check peak purity using the full UV spectrum at several points on each peak [167].
Figure 30 shows overlay chromatograms at 225 nm of OXY standard stressed with acid,
base, heat, light and peroxide showing no interference between OXY, OXY -DEG,
excipients and impurities. It should be noted that during the oxidation stressing a peak
that was observed around retention time of 1.1 minutes is due to the hydrogen peroxide
solution and not oxymetazoline degradant.
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Figure 29: Typical chromatogram for oxymetazoline Hel standard of 100 /!L injection volume
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Figure 30: Overlay chromatogram of OXY standard. From the bottom: Control. Acid, Base, Heat, Light
and Oxidation
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OXY-DEG was observed during the stressing conditions of the oxymetazoline standard
with base. The standard was subjected to 0.1 N of sodium hydroxide at 75°C for one hour.
The solution was cooled to room temperature, neutralized with equivalent amount of 0.1
N hydrochloric acid and analyzed chromatographically. Hydroxide anion in the solution
attack and attach to the carbon at the double bond of the imidazole ring. Furthermore the
attached hydroxyl group converted into a ketone and causes the imidazole ring to open.
That compound is the hydrolysis product of oxymetazoline hydrochloride. Figure 31
shows the base hydrolysis reaction of oxymetazoline.
Linearity of the method was established. Five standard concentrations of
oxymetazoline hydrochloride and OXY-DEG were prepared and injected. Oxymetazoline
was injected at different concentration levels for each method of assay and degradation.

A

linearity graph was prepared by plotting the concentration versus the response of the
actives. The solutions for the oxymetazoline assay method covered a range of 50-150 %
of the hypothetical formulation concentration with corresponding concentration range of
0.05 to 0.15 mg/mL. Table 19 and Figure 32 show the linearity parameters and the
linearity graph for oxymetazoline assay method at wavelength 280 nm respectively.
For the degradation method the OXY solutions cover a range of 70-130% of the
theoretical formulation concentration and 0.1-3.0% range for OXY-DEG relative to
oxymetazoline concentration. The range of the OXY -DEG was determined based on the
ICH guidelines on impurities in new drug substances and new drug products (168-169].
The corresponding concentration range is 0.0007 to 0.0013 mg/mL and 0.0001 to 0.003
mg/mL for the· OXY and. OXY -DEG respectively. The methods were linear in these
ranges with R2 values of 0.999 in both OXY'and OXY-DEG.
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Figure 31: Formation of hydrol yzed product of oxymetazoline
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Target
Concentration
Level
50%
80%
100%
120%
150%
Slope

Concentration
(mglmL)
0.0501
0.08016
0.1002
0.12024
0.1503

Response
(peak Area)

138465.97
221667.44
276757.8
333323.64
414777.48
2761494.17

Y Intercept (%)

296.75

Correlation

0.99997

Table 19: Linearity parameters for Oxymetazoline assay (1.=280 nm)
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Figure 32: Linearity graph of oxymetazoline assay
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Series1
Linear (Series1)

Table 20 and Figure 33 show the linearity parameters and the linearity graph for
oxymetazoline degradation method at wavelength 225 nm respectively. No carryover was
observed into blank injections immediately after the highest level linearity standard of
oxymetazoline, ensuring independence of the samples. In addition,' oxymetazoline HC]
was found to be Hnear with 100 ilL injection volume at the same five concentration levels
as the 10 ilL injection volume. A linearity graph was prepared by plotting the
concentration versus the response of oxymetazoline. Table 21 and Figure 34 show the
linearity parameters and the linearity graph for oxymetazoline assay method with
injection volume 100 ilL and wavelength 280 nm.
This wide linearity calibration range allows the analysis of a variety of possible
formulations containing oxymetazoline HC] and is not limited only to ophthalmic
solutions. It should be noted that method applicability should be explored for each
formulation for possible interferences from the different formulation components that
were used.
System precision was established by six replicate measurements of a hypothetical
formulation containing oxymetazoline HCl. The %RSD for OXY were found to be 0.8
and 0.1 for the assay and degradation methods respectively. Furthermore, to make the
method a QC friendly OXY and OXY-DEG were measured in a single injection. The
system precision was evaluated at 100 III injection volume. Six replicate measurements
of a 100% theoretical standard solution containing oxymetazoline hydrochloride were
injected. The error contributed by the system, independent of the sample preparation, was
less than the acceptance criteria of 2.0 %.
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arget
Concentration
Level

Concentration
(mglmL)

Response
(Peak Area)

70%
80%
90%
100%
130%
Slope

0.000708
111788.48
0.00081
127613.78
0.000911
143316.57
0.001012
160537.21
0.001316
206790.74
156710120.41

Y Intercept (%)

915.35

Correlation

0.9997

Table 20: Linearity parameters for oxymetazoline degradation method (A=225 nm)
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Linearity'of Oxymetazoline
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Figure 33: Linearity graph of oxymetazoline degradation method

127

Target
Concentration
Level

Concentration
(mg/mL)

Response
(peak Area)

50%
70%
100%
120%
150%
Slope

0.05127
1436090.49
0.07169
2011388.93
0.10242
2871951.50
0.12290
3437903.64
0.15362
4281918.60
27799761.12

Y Intercept (%)

18880.01

Correlation

0.99996

Table 21: Linearity parameters for oxymetazoline degradation method (A=225 nm) with 100 J.l.L injection
volume
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linearity of Oxymetazoline lOOul injection
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Figure 34: Linearity graph of oxymetazoline assay method at 280 nm and 100 /-tL injection volume
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The %RSD for assay oxymetazoline was found to be 0.8 and 0.1 for 10 ilL and 100 ilL
injection volumes respectively and the %RSD for oxymetazoline in degradation method
was found to be 0.1 %. In both methods (assay & degradation) including the two different
injection volumes for the assay method the %RSD was well below the 2.0% acceptance
criteria. Comparison tables of the system precision results between the two methods and
the two injections volumes are shown on Table 22a.
The repeatability of the method was evaluated by six identical sample
preparations of a homogeneous batch of an ophthalmic formulation and the results were
found to be within specification. The percent relative standard deviation of the six
preparations for both OXY injections of 10 III and 100 Jll were found to 0.2%.
Comparison table of the results between the two injections volumes are shown on Table
22b. The repeatability of the method was also evaluated for the OXY-DEG by six
identical sample preparations of a homogeneous batch of a real formulation and the
results were found to be within acceptance criteria. The percent relative standard
deviation of the six preparations ofOXY-DEG was found to be 0.5%. In order to further
validate the results, the experiment was conducted again on a different day, using a
different mobile phase, instrument and column. The experimental mean agreements
between the two tests were found to be 0.2 and 2.6 for OXY and OXY -DEG respectively,
both of which are within the acceptance criteria. Further all individual and combined
assay results for both experiments were acceptable. Detailed results ofOXY and OXY
DEG are displayed in Table 22c. All the repeatability results were within acceptance
criteria of 3.0%.
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Oxymetazoline Assay standard
0.10mglmL

Oxymetazoline Degradation
standard
0.10 mg/mL
Area (100pL)

Replicate #

Area (10uL)

Area (lOOuL)

1
2
3'
4
5
6

279044.40
278249.36
274391.35
274136.23
273974.85
276623.72

2877393.58
2877490.53
2878025.81
2877960.56
2879907.73
2880944.21

152361.39
152834.99
152749.44
152629.47
152350.66
152564.84

Mean
%RSD

276069.98
0.8

2878620.40
0.1

152581.80
0.1

I

(a)

Replicate #
1
I

I

Oxymetazoline Theoretical Assay Value: 100% LC
%LC (10 ilL)
%LC (100 ilL)

2
3
4
5
6

100.6
100.6
100.8
100.9
101.2
100.5

100.9
100.6
100.8
100.5
100.6
100.6

Mean
%RSD

100.8
0.2

100.7
0.2

r

I
I
I

I
I

I
I
i

I

(b)

Replicate
1
2
3
4
5
6
Mean
%RSD
Mean Agreement

% Label Claim (% LC)
Oxymetazoline hydrochloride
OXY·Degradant
Experiment 1
Experiment 1
Experiment 2
Experiment 2
100.6
109.2
108.6
100.6
100.6
100.8
110.0
105.5
100.S
lOS.6
105.S
100.2
107.6
100.9
lOS.5
100.5
101.2
100.6
lOS.9
105.1
106.4
100.5
108.7
100.6
109.0
106.4
100.8
100.6
1.3
0.5
0.2
0.2
2.6%
0.2%

Table 22: Experimental results for (a) Comparison of oxymetazoline hydrochloride system precision data
between 10 ilL and 100 ilL injection volumes (b) Comparison of oxymetazoline HCl method precision data
between 10 ilL and 100 ilL injection volume (c) Comparison of oxymetazoline HC] and OXY-DEG for
method precision by two different experiments

131

i
I

i

i

I
i

Accuracy was established by assaying three different concentration levels 70%,
100%, and 130% of the hypothetical fonnulation concentration of OXY. Six preparations
of ophthalmic solutions without oxymetazoline were spiked at each level, with standard
of oxymetazoline and then solutions were injected into HPLC system for the assay
method. For the degradation method accuracy was established by assaying four different
degradant concentration levels 0.1 %, 1.0%, 1.5% and 3.0% of the hypothetical
fonnulation concentration of oxymetazoline hydrochloride. Six preparations of
ophthalmic solutions without oxymetazoline, at each level, were spiked with standard of
OXY -DEG and then solutions were injected into HPLC system. Results are reported in
Table 23. OXY mean recovery values varied from 100.0 to 100.4 % LC and OXY-DEG
mean recovery values varied from 103.6 to 109.0. No bias was observed for the OXY
since the results for the mean recovery from all three accuracy levels were not
significantly lower or higher (±1.5%) than the theoretical value. The accuracy of the
oxymetazoline HCI analytical assay method at 100 III injection volume was detennined at
three working levels 60%, 100% and 140% of the theoretical concentration. Six
preparations of OXY placebo were spiked with a standard at the three working levels of
the theoretical concentration. The results for all three average values met acceptance
criteria and were comparative to the results of the 10 ilL injection volume. OXY mean
recovery values were varied from 99.5 to 100.5 and no bias was observed from all three
levels. Comparison of the results between the two injection volumes at each accuracy
level are shown on Table 24.
The RRF was detennined by spiking OXY-DEG linearity solutions at three levels
(0.1,1.0 and 3.0%) with OXY at the standard concentration. Injections were made in
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Prep #

1
2
3
4
5
6
Mean
%RSD

OxymetazoJine HCI
Mean Recovery Value %LC
70% Level 100% Level 130% Level

OXY .D~radant
Mean Recoverv Value %LC
0.1% Level
1.0% Level 1.5% Level 3.0% Level I

,

99.S
99.9
100.2
100.2
100.2
100.0

99.7
100.5
101.1
100.7
100.4
100.0

99.7
100.2
99.S
100.1
101.2
101.0

109.2
110.0
10S.6
lOS.5
lOS.9
lOS.7

109.S
104.2
104.0
104.1
104.9
104.6

103.5
104.0
104.0
103.S
105.3
104.9

102.7
104.0
104.2
103.1
103.9
104.0

i

100.0
0.2

100.4
0.5

100.3
0.6

109.0
0.5

105.3
2.2

104.3
0.7

103.6
0.6

!

Table 23: Accuracy results (ophthalmic solution without oxymetazoline was spiked at three different levels
for assay of OXY and four levels for the OXY-DEG)
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i

Replicate #

OXYmetazoline HCI
70% Recovery (10111)
60% Recovery (100,",,)

1
2
3
4
5
6

99.8
99.9
100.2
100.2
100.2
100.0

100.2
99.9
100.1
100.2
99.2
100.5

Mean
%RSD

100.0
0.2

100.0

O.S

I

I

I

I

(a)

Replicate #
1
2
3
4
5
6

Mean
%RSD

Oxymetazoline HCI
100% Recovery (10ul)
100% Recovery (100ul)
99.7
100.5

lOLl
100.7
100.4
100.0

100.4

O.S

99.9
100.2
99.7
100.1
100.0
100.3

100.0
0.2

(b)

Replicate #
I

Oxymetazoline HCI
140% Recovery (100 '"")
130% Recovery (10111)

2
3
4
5
6

99.7
100.2
99.8
100.1
101.2
101.0

99.4
100.0
99.6
99.6
99.5
99.6

Mean
%RSD

100.3
0.6

99.6
0.2

(c)

Table 24: Comparison table of oxymetazoline HCI accuracy data between 10 ftL and 100 ",L injection
volume: a) Level 60%, b) Level 100%, c) Level 140%
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i

i

I

triplicate and the average response was used for the determination of the RRF. That
value was corrected for the free base since the salt form of the degradant was used during
the validation. The RRF value was determined to be 0.6993.
The LOD and LOQ were determined by analyzing low concentration linearity
standard solutions of OXY -DEG in triplicate to confirm acceptable results. The LOD was
found to be 0.0001 mglmL for signal to noise ratio more than three and the LOQ was
found to be 0.000025 mg/mL for signal to noise ratio more than twelve.
The methods were unaffected by small, deliberate variations in chromatographic
parameters and mobile phase preparation. The parameters under testing were wavelength,
flow, column temperature, mobile phase ratio and pH of the buffer. The robustness
results have shown that the retention time and the peak shape were not affected by the
parameters under testing. The variation that was observed between the normal method
conditions and the changed parameters were from 0 to ].3% for OXY assay.

The

stabilities of the standard and sample solutions for both OXY and OXY-DEG were
evaluated. The standard of OXY is stable over a period of 168 hours and 240 hours in the
assay method and shows no significant decrease in response over a period of 168 hours
for OXY assay method in both sample and standard. The results are displayed in Table 25.
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Solution stability for Assay method

Solution stability for degradation method

OxymetazoIine Hel Standard

Oxymetazoline Hel Standard

Time Point

Response

% Difference
from Initial

Time Point

Response

Initial

100.7

-

Initial

100.0

.

24 Hours

101.3

0.6

96 Hours

98.2

1.8

72 Hours

102.2

1.5

240 Hours

99.7

0.3

168 Hours

lOlA

0.7

I

% Difference
from Initial

I

Oxymetazoline Hel Sample

OXY -Degradant

% Difference
from Initial

Time Point

Response

99.9

-

Initial

106.8

.

24 Hours

100.6

0.7

96 Hours

104.8

2.0

72 Hours

101.7

1.8

240 Hours

105.1

1.7

168 Hours

99.8

0.1

Time Point

Response

Initial

% Difference
from Initial

I
I

Table 25: Solution stability results for Oxymetazoline standard for both assay and degradation methods.
Solution stability of Oxymetazoline and Oxy-DEG in the sample.
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5.4 Conclusion

In this work, new methods for the determination of oxymetazoline hydrochloride
and its degradation product in ophthalmic solutions are described. Simple dilution
followed by isocratic HPLC with UV -detection is employed, generating a very
straightforward method that might be applicable in a variety of applications. The method
fully separates the oxymetazoline HC} from its degradant and other excipients. Testing
parameters for these methods was performed according to ICH guidelines and met all
acceptance criteria. The methods are precise, accurate, and linear at concentration ranges
encompassing our hypothetical formulations and the known concentrations of many
products containing these substances.
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Overall Conclusions

Over the counter ophthalmic solutions enable people to effectively treat
symptoms of redness, dry eye, tear generation and other irritations of the eye. They are
used worldwide and they are more affordable than their counterpart prescription
ophthalmic solutions. As formulations get more complex with mUltiple components,
targeting multiple symptoms, there is an increasing need for new analytical methods that
are low cost, simple to operate, use straightforward instrumentation, while maintaining
similar requirements to techniques employing more sophisticated instrumentation.
The importance of preservatives in over the counter ophthalmic solutions is well
known given the environment in which these solutions are kept. Often, users they stored
the multidose bottles in medicine cabinets, purses, and pockets, exposed to extreme
>conditions of heat and humidity provide a good environment for microbial growth.
Benzalkonium chloride, one of the most commonly preservative systems in ophthalmic
solutions was studied in this work. Separation of the benzalkonium chloride homologues
from other formulation components was done with a simple, fast isocratic reversed phase
chromatography method using UV detection.

The separation of the homologues is

dependent on mobile phase ratio, pH and buffer strength. The method was applicable to
several different over the counter formulations that were use benzalkonium chloride as a
preservative system.
Lubricants are important substances to ophthalmic formulations because they are
used to control solution viscosity and they are offer medicinal benefits by relieving pain
in inflamed or irritated mucous membranes. Due to their importance in ophthalmic
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solutions several lubricants (polyvinylpyrrolidone, PEG400 and glycerin) were studied in
this work.
The polyvinylpyrrolidone peak was eluted and separated before the void volume
disturbance from other formulation components.

Several unusual chromatographic

situations were used together successfully in this work: Size exclusion chromatography
with UV detection and quantitation of a chromatographic peak eluting before the void
volume. This method provides a model for the analysis of a polymeric component in the
presence of monomeric components in a number of different types of formulations.
A simple size exclusion chromatography method using refractive index detection
was presented. PEG400 and glycerin were separated simultaneously from other
formulation components. In addition, the method appears to be capable of separating
another demulcent,

hydroxylpropyl

methylcellulose

(HPMC)

from

formulation

components. The method provides a model for the simultaneous analysis of polymeric
components in the presence of other formulation components in a number of different
types of formulations.
There are different active components in ophthalmic solutions for the treatment of
variety of symptoms. A major category of active components in ophthalmic solutions is
vasoconstrictors and they are used for the treatment of redness in the eye. A well known
vasoconstrictor that used in the ophthalmic solutions is oxymetazoline. A new simple,
fast, isocratic HPLC with UV -detection method for the determination of oxymetazoline
hydrochloride and its degradation product in ophthalmic solutions was described. The
method fully separates the oxymetazoline HCI from its degradant and other ophthalmic
components and it might be applicable in a variety of other formulations. Stress studies of
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other vasoconstrictors (naphazoline, tetrahydrozoline) with similar chemical structure
indicate that they exhibit the same degradation pathway.
In this work, several straight forward techniques for the analysis of components in
ophthalmic solutions, each of which represents an improvement over previous literature
techniques, are demonstrated.
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